



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/19, C07K 14/52, A61K 38/19, C12N 1/21, 5/10, C07K 16/24, C12N 5/20, C12Q 1/68, C12N 15/11, G01N 33/68</b>		<b>A1</b>	(11) International Publication Number: <b>WO 96/40923</b>
(21) International Application Number: <b>PCT/US96/10114</b>		(81) Designated States: AU, BR, CA, CN, CZ, FI, HU, IL, JP, MX, NO, PL, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>7 June 1996 (07.06.96)</b>		(43) International Publication Date: <b>19 December 1996 (19.12.96)</b>	
(30) Priority Data: 08/479,620      7 June 1995 (07.06.95)      US 08/558,658      16 November 1995 (16.11.95)      US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: ICOS CORPORATION [US/US]; 22021 20th Avenue, S.E., Bothell, WA 98021 (US).			
(72) Inventors: GODISKA, Ronald; 18706 101st Avenue, N.E., Bothell, WA 98011 (US). GRAY, Patrick, W.; 1600 40th Avenue, Seattle, WA 98122 (US).			
(74) Agents: GASS, David, A. et al.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).			

(54) Title: MACROPHAGE DERIVED CHEMOKINE AND CHEMOKINE ANALOGS

## ALIGNMENT OF MDC to C-C CHEMOKINES

Leader				/	Mature				
Hu MDC	MARLQTALLV	VLVLLAVALQ	ATEA		GPYGAN	MEDSVCCRDY	VRYRLPLRVV		50
Hu MCP-3	M-KASAALLC	LLLTAAAFSP	QGLA		QPVGIN	-TSTTCCYRF	INKKIPKQRL		48
Hu MCP-1	M-KVSAALLC	LLLIAATFIP	QGLA		QPDAIN	-APVTCCYNF	TNRKISVQRL		48
Hu MCP-2					QPD-SV	SIPITCCFNV	INRKIPQRL		26
Hu RANTES	M-KVSAAALA	VILIATALCA	PASA		SPY-SS	-DTTPCCFAY	IARPLPRAHI		47
Hu MIP-1 $\beta$	M-KLCVTVLS	LLMLVAAFCS	PALS		APM-GS	DPPTACCFSY	T-REASSNFV		47
Hu MIP-1 $\alpha$	M-QVSTAALA	VLLCTMALCN	QF-S		ASL-AA	DTPTACCFSY	TSRQIPONFI		47
Hu I-309	MQIITTALVC	LLL-AGMWPE	DVDS		KS--MQ	VFFSRCCFSF	AEQEIPLRAI		47
Hu MDC	KH-FYWTSDS	CPRPGVLLT	FRDKEICADP		RVPWVKMILN	KLSQ			93
Hu MCP-3	ESYRRITSSH	CPREAVIFKT	KLDKEICADP		TQKWVQDFMK	HLDKKTQTPKL			99
Hu MCP-1	ASYRRITSSK	CPKEAVIFKT	IVAKEICADP		KQKWVQDSMD	HLDKQTQTPKT			99
Hu MCP-2	ESYTRITNIQ	CPKEAVIFKT	KRGKEVCADP		KERWVRDSMK	HLDQIFQNLKP			76
Hu RANTES	KEYFY-TSGK	CSNPVVFVT	RKNRQVCANP		EKKWVREYIN	SLEMS			91
Hu MIP-1 $\beta$	VDY-YETSSL	CSQPAVVFT	KRSKQVCADP		SESWVQYVY	DLELN			91
Hu MIP-1 $\alpha$	ADYF-ETSSQ	CSKPGVIFLT	KRSRQVCADP		SEEWVQKYVS	DLELSA			92
Hu I-309	LCY-RNTSSI	CSNEGLIFKL	KRGKEACALD		TVGWVQRHRK	MLRHCPSKRK			96

## (57) Abstract

The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated MDC, and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

## MACROPHAGE DERIVED CHEMOKINE AND CHEMOKINE ANALOGS

This application is a continuation-in-part of U.S. Patent Application Serial No. 08/558,658, filed November 16, 1995, which is a  
5 continuation-in-part of U.S. Patent Application Serial No. 08/479,620, filed June 7, 1995.

### FIELD OF THE INVENTION

The present invention relates generally to chemokines and more particularly to purified and isolated polynucleotides encoding a novel human  
10 C-C chemokine, to purified and isolated chemokine protein encoded by the polynucleotides, and to materials and methods for the recombinant production of the novel chemokine protein.

### BACKGROUND

Chemokines, also known as "intercrines" and "SIS cytokines",  
15 comprise a family of small secreted proteins (*e.g.*, 70-100 amino acids and about 8-10 kiloDaltons) which attract and activate leukocytes and thereby aid in the stimulation and regulation of the immune system. The name "chemokine" is derived from chemotactic cytokine, and refers to the ability of these proteins to stimulate chemotaxis of leukocytes. Indeed, chemokines  
20 may comprise the main attractants for inflammatory cells into pathological tissues. See generally, Baggiolini *et al.*, *Advances in Immunology*, 55:97-179 (1994). While leukocytes comprise a rich source of chemokines, several chemokines are expressed in a multitude of tissues. *Id.*, Table II.

Previously identified chemokines generally exhibit 20-70%  
25 amino acid identity to each other and contain four highly-conserved cysteine residues. Based on the relative position of the first two of these cysteine residues, chemokines have been further classified into two subfamilies. In the "C-X-C" or " $\alpha$ " subfamily, encoded by genes localized to human chromosome

- 2 -

4, the first two cysteines are separated by one amino acid. In the "C-C" or "β" subfamily, encoded by genes on human chromosome 17, the first two cysteines are adjacent. X-ray crystallography and NMR studies of several chemokines have indicated that, in each family, the first and third cysteines  
5 form a first disulfide bridge, and the second and fourth cysteines form a second disulfide bridge, strongly influencing the native conformation of the proteins. In humans alone, nearly ten distinct sequences have been described for each chemokine subfamily. Chemokines of both subfamilies have characteristic leader sequences of twenty to twenty-five amino acids.

10 The C-X-C chemokines, which include IL-8, GROα/β/γ, platelet basic protein, Platelet Factor 4 (PF4), IP-10, and others, share approximately 25% to 60% identity when any two amino acid sequences are compared (except for the GROα/β/γ members, which are 84-88% identical with each other). Most of the C-X-C chemokines (excluding IP-10 and  
15 Platelet Factor 4) share a common E-L-R tri-peptide motif upstream of the first two cysteine residues, and are potent stimulants of neutrophils, causing rapid shape change, chemotaxis, respiratory bursts, and degranulation. These effects are mediated by seven-transmembrane-domain rhodopsin-like G protein-coupled receptors; a receptor specific for IL-8 has been cloned by  
20 Holmes *et al.*, *Science*, 253:1278-80 (1991), while a similar receptor (77% identity) which recognizes IL-8, GRO and NAP2 has been cloned by Murphy and Tiffany, *Science*, 253:1280-83 (1991). Progressive truncation of the N-terminal amino acid sequence of certain C-X-C chemokines, including IL-8, is associated with marked increases in activity.

25 The C-C chemokines, which include Macrophage Inflammatory Proteins MIP-1α and MIP-1β, Monocyte chemoattractant proteins 1, 2, and 3 (MCP-1/2/3), RANTES, I-309, and others, share 25% to 70% amino acid identity with each other. All of the previously-identified C-C chemokines activate monocytes, causing calcium flux and chemotaxis. More selective  
30 effects are seen on lymphocytes, for example, T lymphocytes, which respond

- 3 -

best to RANTES. Five seven-transmembrane-domain G protein-coupled receptors for C-C chemokines have been cloned to date, including a C-C chemokine receptor-1 (CCR1) which recognizes MIP-1 $\alpha$  and RANTES (Neote *et al.*, *Cell*, 72:415-425 (1993)), and a CCR2 receptor which recognizes MCP-1 (Charo *et al.*, *Proc. Nat. Acad. Sci.*, 91:2752-56 (1994)); CCR3, which recognizes eotaxin (Combadiere, *J. Biol. Chem.*, 270:16491 (1995)); CCR4, which recognized MIP-1 $\alpha$ , RANTES, and MCP-1 (Power *et al.*, *J. Biol. Chem.*, 270:19495 (1995)); and CCR5, which recognizes MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES (Samson *et al.*, *Biochemistry*, 35:3362 (1996)).

10           The roles of a number of chemokines, particularly IL-8, have been well documented in various pathological conditions. See generally Baggiolini *et al.*, *supra*, Table VII. Psoriasis, for example, has been linked to over-production of IL-8, and several studies have observed high levels of IL-8 in the synovial fluid of inflamed joints of patients suffering from  
15   rheumatic diseases, osteoarthritis, and gout.

          The role of C-C chemokines in pathological conditions also has been documented, albeit less comprehensively than the role of IL-8. For example, the concentration of MCP-1 is higher in the synovial fluid of patients suffering from rheumatoid arthritis than that of patients suffering from other  
20   arthritic diseases. The MCP-1 dependent influx of mononuclear phagocytes may be an important event in the development of idiopathic pulmonary fibrosis. The role of C-C chemokines in the recruitment of monocytes into atherosclerotic areas is currently of intense interest, with enhanced MCP-1 expression having been detected in macrophage-rich arterial wall areas but not  
25   in normal arterial tissue. Expression of MCP-1 in malignant cells has been shown to suppress the ability of such cells to form tumors *in vivo*. (See U.S. Patent No. 5,179,078, incorporated herein by reference.) A need therefore exists for the identification and characterization of additional C-C chemokines, to further elucidate the role of this important family of molecules in

- 4 -

pathological conditions, and to develop improved treatments for such conditions utilizing chemokine-derived products.

Chemokines of the C-C subfamily have been shown to possess utility in medical imaging, *e.g.*, for imaging sites of infection, inflammation, and other sites having C-C chemokine receptor molecules. See, *e.g.*, Kunkel *et al.*, U.S. Patent No. 5,413,778, incorporated herein by reference. Such methods involve chemical attachment of a labelling agent (*e.g.*, a radioactive isotope) to the C-C chemokine using art recognized techniques (see, *e.g.*, U.S. Patent Nos. 4,965,392 and 5,037,630, incorporated herein by reference), administration of the labelled chemokine to a subject in a pharmaceutically acceptable carrier, allowing the labelled chemokine to accumulate at a target site, and imaging the labelled chemokine *in vivo* at the target site. A need in the art exists for additional new C-C chemokines to increase the available arsenal of medical imaging tools.

The C-C chemokines RANTES, MIP- $\alpha$ , and MIP-1 $\beta$  also have been shown to be the primary mediators of the suppressive effect of human T cells on the human immunodeficiency virus (HIV), the agent responsible for causing human Acquired Immune Deficiency Syndrome (AIDS). These chemokines show a dose-dependent ability to inhibit specific strains of HIV from infecting cultured T cell lines [Cocchi *et al.*, *Science*, 270:1811 (1995)]. However, not all tested strains of the virus are equally susceptible to this inhibition; therefore, a need exists for additional C-C chemokines for use as inhibitors of strains of HIV.

More generally, due to the importance of chemokines as mediators of chemotaxis and inflammation, a need exists for the identification and isolation of new members of the chemokine family to facilitate modulation of inflammatory and immune responses.

For example, substances that promote inflammation may promote the healing of wounds or the speed of recovery from conditions such as pneumonia, where inflammation is important to eradication of infection.

- 5 -

Modulation of inflammation is similarly important in pathological conditions manifested by inflammation. Crohn's disease, manifested by chronic inflammation of all layers of the bowel, pain, and diarrhea, is one such pathological condition. The failure rate of drug therapy for Crohn's disease is relatively high, and the disease is often recurrent even in patients receiving surgical intervention. The identification, isolation, and characterization of novel chemokines facilitates modulation of inflammation.

Similarly, substances that induce an immune response may promote palliation or healing of any number of pathological conditions. Due to the important role of leukocytes (*e.g.*, neutrophils and monocytes) in cell-mediated immune responses, and due to the established role of chemokines in leukocyte chemotaxis, a need exists for the identification and isolation of new chemokines to facilitate modulation of immune responses.

Additionally, the established correlation between chemokine expression and inflammatory conditions and disease states provides diagnostic and prognostic indications for the use of chemokines, as well as for antibody substances that are specifically immunoreactive with chemokines; a need exists for the identification and isolation of new chemokines to facilitate such diagnostic and prognostic indications.

In addition to their ability to attract and activate leukocytes, some chemokines, such as IL-8, have been shown to be capable of affecting the proliferation of non-leukocytic cells. See Tuschil, *J. Invest. Dermatol.*, 99:294-298 (1992). A need exists for the identification and isolation of new chemokines to facilitate modulation of such cell proliferation.

For all of the aforementioned reasons, a need exists for recombinant methods of production of newly discovered chemokines, which methods facilitate clinical applications involving the chemokines and chemokine inhibitors.

- 6 -

**SUMMARY OF THE INVENTION**

The present invention provides novel purified and isolated polynucleotides and polypeptides that fulfill one or more of the needs outlined above.

5 For example, the invention provides purified and isolated polynucleotides (*i.e.*, DNA and RNA, both sense and antisense strands) encoding a novel human chemokine of the C-C subfamily, herein designated "Macrophage Derived Chemokine" or "MDC". Preferred DNA sequences of the invention include genomic and cDNA sequences and chemically  
10 synthesized DNA sequences.

The nucleotide sequence of a cDNA, designated MDC cDNA, encoding this chemokine, is set forth in SEQ ID NO: 1, which sequence includes 5' and 3' non-coding sequences. A preferred DNA of the present invention comprises nucleotides 20 to 298 of SEQ ID NO. 1, which  
15 nucleotides comprise the MDC coding sequence.

The MDC protein comprises a putative twenty-four amino acid signal sequence at its amino terminus. A preferred DNA of the present invention comprises nucleotides 92 to 298 of SEQ ID NO. 1, which nucleotides comprise the putative coding sequence of the mature (secreted)  
20 MDC protein, without the signal sequence.

The amino acid sequence of chemokine MDC is set forth in SEQ ID NO: 2. Preferred polynucleotides of the present invention include, in addition to those polynucleotides described above, polynucleotides that encode the amino acid sequence set forth in SEQ ID NO:2, and that differ  
25 from the polynucleotides described in the preceding paragraphs only due to the well-known degeneracy of the genetic code.

Similarly, since twenty-four amino acids (positions -24 to -1) of SEQ ID NO: 2 comprise a putative signal peptide that is cleaved to yield the mature MDC chemokine, preferred polynucleotides include those which  
30 encode amino acids 1 to 69 of SEQ ID NO: 2. Thus, a preferred



- 7 -

polynucleotide is a purified polynucleotide encoding a polypeptide having an amino acid sequence comprising amino acids 1-69 of SEQ ID NO: 2.

Among the uses for the polynucleotides of the present invention is the use as a hybridization probe, to identify and isolate genomic DNA  
5 encoding human MDC, which gene is likely to have a three exon/two intron structure characteristic of C-C chemokines genes. (*See Baggiolini et al., supra*); to identify and isolate DNAs having sequences encoding non-human proteins homologous to MDC; to identify human and non-human chemokines having similarity to MDC; and to identify those cells which express MDC and  
10 the conditions under which this protein is expressed.

Hybridization probes of the invention also have diagnostic utility, e.g., for screening for inflammation in human tissue, such as colon tissue. More particularly, hybridization studies using an MDC polynucleotide hybridization probe distinguished colon tissue of patients with Crohn's disease  
15 (MDC hybridization detected in epithelium, lamina propria, Payer's patches, and smooth muscle) from normal human colon tissue (no hybridization above background).

Generally speaking, a continuous portion of the MDC cDNA of the invention that is at least about 14 nucleotides, and preferably about 18  
20 nucleotides, is useful as a hybridization probe of the invention. Thus, in one embodiment, the invention includes a DNA comprising a continuous portion of the nucleotide sequence of SEQ ID NO: 1 or of the non-coding strand complementary thereto, the continuous portion comprising at least 18 nucleotides, the DNA being capable of hybridizing under stringent conditions  
25 to a coding or non-coding strand of a human MDC gene. For diagnostic utilities, hybridization probes of the invention preferably show hybridization specificity for MDC gene sequences. Thus, in a preferred embodiment, hybridization probe DNAs of the invention fail to hybridize under the stringent conditions to other human chemokine genes (e.g., MCP-1 genes, MCP-2

- 8 -

genes, MCP-3 genes, RANTES genes, MIP-1 $\alpha$  genes, MIP-1 $\beta$  genes, and I-309 genes, etc.).

In another aspect, the invention provides a purified polynucleotide which hybridizes under stringent conditions to the non-coding strand of the DNA of SEQ ID NO: 1. Similarly, the invention provides a purified polynucleotide which, but for the redundancy of the genetic code, would hybridize under stringent conditions to the non-coding strand of the DNA of SEQ ID NO: 1. Exemplary stringent hybridization conditions are as follows: hybridization at 42°C in 5X SSC, 20 mM NaPO<sub>4</sub>, pH 6.8, 50% formamide; and washing at 42°C in 0.2X SSC. Those skilled in the art understand that it is desirable to vary these conditions empirically based on the length and the GC nucleotide base content of the sequences to be hybridized, and that formulas for determining such variation exist. [See, e.g., Sambrook et al., *Molecular Cloning: a Laboratory Manual*. Second Edition, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1989).]

In another aspect, the invention includes plasmid and viral DNA vectors incorporating DNAs of the invention, including any of the DNAs described above or elsewhere herein. Preferred vectors include expression vectors in which the incorporated MDC-encoding cDNA is operatively linked to an endogenous or heterologous expression control sequence. Such expression vectors may further include polypeptide-encoding DNA sequences operably linked to the MDC-encoding DNA sequences, which vectors may be expressed to yield a fusion protein comprising the MDC polypeptide of interest.

In another aspect, the invention includes a prokaryotic or eukaryotic host cell stably transfected or transformed with a DNA or vector of the present invention. In preferred host cells, the mature MDC polypeptide encoded by the DNA or vector of the invention is expressed. The DNAs, vectors, and host cells of the present invention are useful, e.g., in methods for the recombinant production of large quantities of MDC polypeptides of the

- 9 -

present invention. Such methods are themselves aspects of the invention. For example, the invention includes a method for producing MDC wherein a host cell of the invention is grown in a suitable nutrient medium and MDC protein is isolated from the cell or the medium.

5           In yet another aspect, the invention includes purified and isolated MDC polypeptides. A preferred peptide is a purified chemokine polypeptide having an amino acid sequence comprising amino acids 1 to 69 of SEQ ID NO: 2. The polypeptides of the present invention may be purified from natural sources, but are preferably produced by recombinant procedures, using the DNAs, vectors, and/or host cells of the present invention, or are chemically synthesized. Purified polypeptides of the invention may be glycosylated or non-glycosylated, water soluble or insoluble, oxidized, reduced, etc., depending on the host cell selected, recombinant production method, isolation method, processing, storage buffer, and the like.

15           Moreover, an aspect of the invention includes MDC polypeptide analogs wherein one or more amino acid residues is added, deleted, or replaced from the MDC polypeptides of the present invention, which analogs retain one or more of the biological activities characteristic of the C-C chemokines. The small size of MDC facilitates chemical synthesis of such polypeptide analogs, which may be screened for MDC biological activities (e.g., the ability to induce macrophage chemotaxis, or inhibit monocyte chemotaxis) using the many activity assays described herein. Alternatively, such polypeptide analogs may be produced recombinantly using well-known procedures, such as site-directed mutagenesis of MDC-encoding DNAs of the invention.

25           In a related aspect, the invention includes polypeptide analogs wherein one or more amino acid residues is added, deleted, or replaced from the MDC polypeptides of the present invention, which analogs lack the biological activities of C-C chemokines or MDC, but which are capable of competitively or non-competitively inhibiting the binding of MDC

30

- 10 -

polypeptides with a C-C chemokine receptor. Such polypeptides are useful, *e.g.*, for modulating the biological activity of endogenous MDC in a host, as well as useful for medical imaging methods described above.

Certain specific analogs of MDC are contemplated to modulate the structure, intermolecular binding characteristics, and biological activities of MDC. For example, amino-terminal (N-terminal) and carboxy-terminal (C-terminal) deletion analogs (truncations) are specifically contemplated to change MDC structure and function.

Additionally, the following single-amino acid alterations (alone or in combination) are specifically contemplated: (1) substitution of a non-basic amino acid for the basic arginine and/or lysine amino acids at positions 24 and 27, respectively, of SEQ ID NO: 2; (2) substitution of a charged or polar amino acid (*e.g.*, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine or cysteine) for the tyrosine amino acid at position 30 of SEQ ID NO: 2, the tryptophan amino acid at position 59 of SEQ ID NO: 2, and/or the valine amino acid at position 60 of SEQ ID NO: 2; and (3) substitution of a basic or small, non-charged amino acid (*e.g.*, lysine, arginine, histidine, glycine, alanine) for the glutamic acid amino acid at position 50 of SEQ ID NO: 2. Specific analogs having these amino acid alterations are encompassed by the following formula (SEQ ID NO: 25):

Met	Ala	Arg	Leu	Gln	Thr	Ala	Leu	Leu	Val	Val	Leu	Val	Leu	Leu	Ala
-24				-20					-15					-10	

Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	Gly	Ala	Asn	Met	Glu
			-5					1				5			

Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	Arg	Leu	Pro	Leu	Xaa
	10					15					20				

Val	Val	Xaa	His	Phe	Xaa	Trp	Thr	Ser	Asp	Ser	Cys	Pro	Arg	Pro	Gly
25					30					35					40

Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Xaa	Ile	Cys	Ala	Asp	Pro	Arg
30					45				50					55	

- 11 -

Val Pro Xaa Xaa Lys Met Ile Leu Asn Lys Leu Ser Gln  
60 65

wherein the amino acid at position 24 is selected from the group consisting of arginine, glycine, alanine, valine, leucine, isoleucine, proline, serine, threonine, phenylalanine, tyrosine, tryptophan, aspartate, glutamate, asparagine, glutamine, cysteine, and methionine; wherein the amino acid at position 27 is independently selected from the group consisting of lysine, glycine, alanine, valine, leucine, isoleucine, proline, serine, threonine, phenylalanine, tyrosine, tryptophan, aspartate, glutamate, asparagine, glutamine, cysteine, and methionine; wherein the amino acid at position 30 is independently selected from the group consisting of tyrosine, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, and cysteine; wherein the amino acid at position 50 is independently selected from the group consisting of glutamic acid, lysine, arginine, histidine, glycine, and alanine; wherein the amino acid at position 59 is independently selected from the group consisting of tryptophan, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, and cysteine; and wherein the amino acid at position 60 is independently selected from the group consisting of valine, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, and cysteine. Such MDC polypeptide analogs are specifically contemplated to modulate the binding characteristics of MDC to chemokine receptors and/or other molecules (e.g., heparin, glycosaminoglycans, erythrocyte chemokine receptors) that are considered to be important in presenting MDC to its receptor. In one preferred embodiment, MDC polypeptide analogs of the invention comprise amino acids 1 to 69 of SEQ ID NO: 25.

The following additional analogs have been synthesized and also are intended as aspects of the invention: (a) a polypeptide comprising a sequence of amino acids identified by positions 1 to 70 of SEQ ID NO: 30; (b) a polypeptide comprising a sequence of amino acids identified by positions 9 to 69 of SEQ ID NO: 2; (c) a polypeptide comprising a sequence of amino

- 12 -

acids identified by positions 1 to 69 of SEQ ID NO: 31; and (d) a polypeptide comprising a sequence of amino acids identified by positions 1 to 69 of SEQ ID NO: 32.

5 In related aspects, the invention provides purified and isolated polynucleotides encoding such MDC polypeptide analogs, which polynucleotides are useful for, e.g., recombinantly producing the MDC polypeptide analogs; plasmid and viral vectors incorporating such polynucleotides, and prokaryotic and eukaryotic host cells stably transformed with such DNAs or vectors.

10 In another aspect, the invention includes antibody substances (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric or humanized antibodies, and the like) which are immunoreactive with MDC polypeptides and polypeptide analogs of the invention. Such antibodies are useful, e.g., for purifying polypeptides of the present invention, for  
15 quantitative measurement of endogenous MDC in a host, e.g., using well-known ELISA techniques, and for modulating binding of MDC to its receptor(s). The invention further includes hybridoma cell lines that produce antibody substances of the invention.

Recombinant MDC polypeptides and polypeptide analogs of the  
20 invention may be utilized in a like manner to antibodies in binding reactions, to identify cells expressing receptor(s) of MDC and in standard expression cloning techniques to isolate polynucleotides encoding the receptor(s). Such MDC polypeptides, MDC polypeptide analogs, and MDC receptor polypeptides are useful for modulation of MDC chemokine activity, and for  
25 identification of polypeptide and chemical (e.g., small molecule) MDC agonists and antagonists.

Additional aspects of the invention relate to pharmaceutical utilities of MDC polypeptides and polypeptide analogs of the invention. For example, MDC has been shown to modulate leukocyte chemotaxis. In  
30 particular, MDC has been shown to induce macrophage chemotaxis and to

- 13 -

inhibit monocyte chemotaxis. Thus, in one aspect, the invention includes a method for modulating (e.g., up-regulating or down-regulating) leukocyte chemotaxis in a mammalian host comprising the step of administering to the mammalian host an MDC polypeptide or polypeptide analog of the invention, wherein the MDC polypeptide or MDC polypeptide analog modulates leukocyte chemotaxis in the host. In preferred methods, the leukocytes are monocytes and/or macrophages. For example, empirically determined quantities of MDC are administered (e.g., in a pharmaceutically acceptable carrier) to induce macrophage chemotaxis or to inhibit monocyte chemotaxis, whereas inhibitory MDC polypeptide analogs are employed to achieve the opposite effect.

In another aspect, the invention provides a method for palliating an inflammatory condition in a patient, the condition characterized by at least one of (i) monocyte chemotaxis toward a site of inflammation in said patient or (ii) fibroblast cell proliferation, the method comprising the step of administering to the patient a therapeutically effective amount of MDC. In one embodiment, a therapeutically effective amount of MDC is an amount capable of inhibiting monocyte chemotaxis. In another embodiment, a therapeutically effective amount of MDC is an amount capable of inhibiting fibroblast cell proliferation. Such therapeutically effective amounts are empirically determined using art-recognized dose-response assays.

As an additional aspect, the invention provides a pharmaceutical composition comprising an MDC polypeptide or polypeptide analog of the invention in a pharmaceutically acceptable carrier. Similarly, the invention relates to the use of composition according to the invention for the treatment of disease states, e.g., inflammatory disease states. In one embodiment, the inflammatory disease state is characterized by monocyte chemotaxis toward a site of inflammation in a patient having the disease state. In another embodiment, the inflammatory disease state is characterized by fibroblast cell proliferation in a patient having the disease state.

- 14 -

The foregoing aspects and numerous additional aspects will be apparent from the drawing and detailed description which follow.

#### **BRIEF DESCRIPTION OF THE DRAWING**

FIGURE 1 is a comparison of the amino acid sequence of  
5 human MDC (SEQ ID NO: 2) with the amino acid sequences of other,  
previously characterized human C-C chemokines: MCP-3 [Van Damme *et al.*, *J. Exp. Med.*, 176:59 (1992)] (SEQ ID NO: 18); MCP-1 [Matsushima *et al.*, *J. Exp. Med.*, 169:1485 (1989)] (SEQ ID NO: 19); MCP-2 (mature form)  
[Van Damme *et al.*, *supra*; Chang *et al.*, *Int. Immunol.*, 1:388 (1989)] (SEQ  
10 ID NO: 20); RANTES [Schall *et al.*, *J. Immunol.*, 141:1018 (1988)] (SEQ ID  
NO: 21); MIP-1 $\beta$  [Brown *et al.*, *J. Immunol.*, 142:679 (1989)] (SEQ ID NO:  
22); MIP-1 $\alpha$  [Nakao *et al.*, *Mol. Cell Biol.*, 10:3646 (1990)] (SEQ ID NO:  
23); and I-309 [Miller *et al.*, *J. Immunol.*, 143:2907 (1989)] (SEQ ID NO:  
24). A slash "/" marks the site at which putative signal peptides are cleaved.  
15 Dashes are inserted to optimize alignment of the sequences.

Figure 2 is a graph depicting the chemotactic effect (measured  
in fluorescence units) of increasing concentrations of MDC on human  
mononuclear cell migration in a chemotaxis assay. Closed circles show the  
response of human mononuclear cells derived from the cell line THP-1. The  
20 open diamond shows the response to the positive control, zymosan activated  
serum (ZAS).

Figure 3 is a graph depicting the chemotactic effect (measured  
in fluorescence units) of increasing concentrations of MDC on human  
polymorphonuclear (pmn) leukocyte migration. Closed circles show response  
25 to MDC, and an open diamond shows the response to the positive control, IL-  
8.

Figure 4 is a graph depicting the chemotactic effect (measured  
in fluorescence units) of increasing concentrations of MDC on macrophage  
and monocyte migration. Closed circles show the response to MDC of



- 15 -

macrophages derived from the cell line THP-1. Open circles show the response to MDC of monocytes derived from the cell line THP-1.

Figure 5 is a graph depicting the chemotactic effect (measured in fluorescence units) of increasing concentrations of MDC on guinea pig peritoneal macrophage migration. Closed circles show the response of macrophages to MDC. An open triangle shows the response to the positive control, zymosan activated serum (ZAS).

Figure 6 is a graph depicting the chemotactic-inhibitory effect (measured in fluorescence units) of increasing concentrations of MDC on THP-1 monocyte migration induced by MCP-1. Closed circles depict the chemotactic-inhibitory effects of MDC where chemotaxis has been induced by MCP-1. Open circles depict the chemotactic-inhibitory effects of MDC in a control experiment wherein only the basal medium (RPMI with 0.2% BSA (RBSA), no MCP-1) was employed. The zero point on the x axis corresponds to the response of cells to MCP-1 and RBSA in the absence of any MDC.

Figure 7 is a graph depicting the effect (measured in counts per minute (cpm)) of increasing concentrations of MDC on fibroblast proliferation. Closed circles depict the proliferative response with purified MDC that was recombinantly produced in CHO cells (Example 10F). Open circles depict the response with chemically synthesized MDC (Example 11).

Figure 8 schematically depicts the construction of mammalian expression vector pDC1.

### DETAILED DESCRIPTION

The present invention is illustrated by the following examples related to a human cDNA, designated MDC cDNA, encoding a novel C-C chemokine designated MDC (for "macrophage-derived chemokine"). More particularly, Example 1 describes the isolation of a partial MDC cDNA from a human macrophage cDNA library. Example 2 describes the isolation of

- 16 -

additional cDNAs from the cDNA library using the cDNA from Example 1 as a probe, one of these additional cDNAs containing the entire MDC coding sequence. Additionally, Example 2 presents a composite MDC cDNA nucleotide sequence and presents a characterization of the deduced amino acid sequence of the chemokine (MDC) encoded thereby. In Example 3, experiments are described which reveal the level of MDC gene expression in various human tissues. The greatest MDC gene expression was observed in the thymus, with much weaker expression detectable in spleen and lung tissues. Example 4 describes more particularly the expression of the MDC gene during monocyte maturation into macrophages and during inducement of HL60 cell differentiation to a macrophage-like cell type.

Since MDC gene expression was detected in thymus and spleen in Example 3, *in situ* hybridization studies were conducted to localize further the MDC gene expression in these tissues. Moreover, *in situ* hybridization revealed a correlation between elevated MDC gene expression in intestinal tissue and Crohn's disease. These *in situ* hybridization experiments are described in Example 5.

Example 6 describes the recombinant production of MDC as a GST fusion protein in prokaryotic cells, as well as the cleavage of the fusion protein and purification of the recombinant MDC. Example 7 describes the construction of an alternative DNA construct useful for expression of recombinant MDC protein, and describes the production of MDC by a bacterial host transformed with this construct.

Example 8 provides experimental protocols for purification of the recombinant MDC produced as described in Example 7. Examples 9 and 10 provide experimental protocols for the recombinant production of MDC in yeast and mammalian cells, respectively. In addition, Example 10 provides protocols for purification of recombinant MDC. Example 11 describes production of MDC and MDC polypeptide analogs by peptide synthesis.

- 17 -

Examples 12-17 provide protocols for the determination of MDC biological activities. For instance, Example 12 provides an assay of MDC effects upon basophils, mast cells, and eosinophils. Example 13 describes assays of chemoattractant and cell-activation properties of MDC on monocytes/macrophages, neutrophils, and granulocytes.

Examples 14-17 provide protocols for the determination of MDC biological activities *in vivo*. Example 14 provides an MDC tumor growth- inhibition assay. Examples 15 and 16 provide protocols for assaying MDC activity via intraperitoneal and subcutaneous injection, respectively. Example 17 provides protocols for determining the myelosuppressive activity of MDC.

Example 18 provides a protocol for generating monoclonal antibodies that are specifically immunoreactive with MDC.

The remaining examples provide additional MDC activity assays. For example, Example 19 provides a calcium flux assay for determining the ability of MDC to induce cellular activation. Example 20 provides an assay for determining the HIV anti-proliferative effects of MDC. Example 21 demonstrates the anti-proliferative effects of MDC on fibroblasts. Example 22 provides *in vitro* assays for the effects of MDC upon the proliferation of additional cell types. Example 23 provides an *in vivo* assay for determining the anti-proliferative effects of MDC on fibroblasts. Example 24 provides assays for identifying MDC modulators.

### Example 1

#### Isolation of a Partial C-C chemokine cDNA

A partial cDNA for a new C-C chemokine was isolated as follows. Poly A<sup>+</sup> RNA was harvested from peripheral blood monocyte-derived macrophages. Double-stranded, blunt-ended cDNA was generated using the Invitrogen Copy Kit (San Diego, CA) and *Bst*XI adapters were ligated to the cDNA prior to insertion into the mammalian expression vector,

- 18 -

pRc/CMV (Invitrogen) [See, Tjoelker *et al.*, *Nature*, 374:549-552 (1995)]. *E. coli* XL1-Blue bacteria (Stratagene, La Jolla, CA) were transformed via electroporation with the plasmid cDNA library and plated onto 986 plates containing 100 µg/ml carbenicillin (approximately 3000 transformants per plate). After overnight growth at 37°C, the bacteria were scraped off of each plate to form 986 bacterial pools. Plasmid DNA was isolated from each of the 986 bacterial pools using the Magic Miniprep DNA Purification System (Promega, Madison, WI) according to the manufacturer's directions.

The purified plasmid DNA pools were used to isolate individual cDNA clones for further characterization, as follows: Plasmid DNA from individual pools was used to transform *E. coli* XL1-Blue cells, which were plated and grown overnight as described above. Individual transformants were randomly selected and grown overnight in 3 ml of LB media supplemented with carbenicillin for plasmid purification using the Wizard Miniprep Purification system (Promega) with the following alteration: 250 mg of diatomaceous earth (Sigma Chem. Co., St. Louis MO) was added to the DNA binding resin provided by the manufacturer. Purified plasmid DNA was sequenced on a Model 373 automated sequencer (Applied Biosystems, Foster City, CA) using primer JHSP6:

20                   5' GAACTATAGAATAGGGC 3' (SEQ ID NO: 3).

This primer hybridizes to plasmid vector pRc/CMV adjacent to the cloning site.

The nucleotide and deduced amino acid sequences of individual cDNAs were compared to nucleotide and peptide sequence databases to determine which of the clones encoded proteins with similarity to known inflammatory mediators. Sequence comparisons were performed on December 14, 1994, by the BLAST Network Service of the National Center for Biotechnology Information (e-mail: "blast@ncbi.nlm.nih.gov"), using the alignment algorithm of Altschul *et al.*, *J. Mol. Biol.*, 215: 403-410 (1990).

- 19 -

The sequence analysis revealed that a portion of one of the isolated macrophage cDNA clones, designated pMP390, contained a gene sequence having approximately 60-70% identity with previously-identified chemokine genes, including the human MCP-3 gene and rat MIP-1 $\beta$  gene.

5           The 2.85 kb cDNA insert of pMP390 was subcloned into the vector pBluescript SK<sup>-</sup> (Stratagene, La Jolla CA) to facilitate complete sequencing. Nested deletions beginning from the poly-A tail were created by digestion, using Promega's Erase-a-Base System (Madison WI). The deletion plasmids were recircularized, cloned in *E. coli*, purified, and sequenced using  
10   the M13, T3.1, and T7.1 primers depicted below:

(SEQ ID NO: 4)

M13: 5' GTAAAACGACGGCCAGT 3'

(SEQ ID NO: 5)

T3.1: 5' AATTAACCCTCACTAAAGGG 3'

15           (SEQ ID NO: 6)

T7.1: 5' GTAATACGACTCACTATAGGGC 3'

The complete sequence of this pMP390 cDNA corresponds to nucleotides 73 to 2923 of SEQ ID NO: 1 (and to deduced amino acids -6 to 69 of SEQ ID NO 2). The sequence that was originally compared to database sequences  
20   corresponds to nucleotides 73 to 610 of SEQ ID NO: 1.

- 20 -

**Example 2****Isolation of additional cDNA clones having  
the complete MDC coding sequence**

Using the pMP390 cDNA clone isolated in Example 1,  
5 additional cDNA clones were isolated from the same human macrophage  
cDNA library, these additional cDNAs containing additional 5' sequence and  
encoding the complete amino acid sequence of a macrophage derived  
chemokine.

First, forty of the 986 plasmid DNA pools derived from the  
10 macrophage cDNA library (Example 1) were screened by PCR to identify  
pools containing additional cDNA clones of interest. From the pMP390  
cDNA sequence obtained in Example 1, synthetic oligonucleotide PCR  
primers 390-1F (deposited as SEQ ID NO: 7) and 390-2R (SEQ ID NO: 8)  
were constructed to amplify a 211 base pair sequence of the chemokine gene  
15 partially encoded by pMP390:

390-1F: 5'TCTATCTAGAGGCCCTACGGCGCCAACATGGAAG  
3'

390-2R: 5' CACCGGATCCTCATTGGCTCAGCTTATTGAGAA 3'

Primer 390-1F corresponds to nucleotides 91-116 of SEQ ID NO: 1, preceded  
20 by the recognition site for the restriction endonuclease *Xba* I and 4 additional  
bases to facilitate cleavage by the enzyme; primer 390-2R is complementary  
to nucleotides 301-279 of SEQ ID NO: 1, fused to the recognition site for the  
enzyme *Bam*H I, which is flanked by 4 additional bases. The *Xba* I and  
*Bam*H I sites were added to facilitate cloning of the resultant fragment.

25 The 50 ul PCR reaction mixture for each selected plasmid pool  
contained 0.2 ug of plasmid DNA; 1.5 mM MgCl<sub>2</sub>; 50 mM KCl; 10 mM  
Tris, pH 8.4; 0.2 mM each dNTP; 10 ug/ml each primer; and 0.5 ul Taq  
polymerase (5 U/ul) (Boehringer Mannheim Biochemicals (BMB),  
Indianapolis, IN). The reactions were incubated for 4 minutes at 94°C,

- 21 -

followed by 30 cycles of denaturation for 15 seconds at 94°C, annealing for 15 seconds at 60°C, and extension for 30 seconds at 72°C.

The PCR reaction products were electrophoresed through 2% agarose gels (Life Technologies, Inc., Gaithersburg, MD) in 0.5X TBE buffer [Sambrook et al., *Molecular Cloning: a Laboratory Manual*. Second Edition, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1989)], and visualized with Ethidium Bromide. Of the forty plasmid pools screened, six produced an intense band corresponding to the expected 230 base pair PCR fragment (which includes 211 bp of chemokine gene sequence flanked by the *Xba* I and *Bam*H I restriction sites) suggesting the presence of one or more plasmids containing gene sequences related to pMP390.

To isolate such related clones, aliquots from three of the six positive plasmid pools were electroporated into *E. coli* XL1-Blue cells, which were plated and grown overnight as described in Example 1. Colonies were transferred to nitrocellulose membranes and prepared for hybridization following standard protocols (Sambrook *et al.*, *supra*).

A radiolabelled MDC probe for screening the filters was prepared as follows: the 2.85 kb DNA fragment containing the MDC cDNA was excised from pMP390 by restriction enzyme digestion, purified by agarose gel electrophoresis in TAE Buffer (Sambrook, *et al.*, *supra*), electroeluted, extracted with phenol and chloroform, and precipitated with ethanol. The purified fragment (250 ng) was labelled using the Random Primed DNA Labelling Kit (BMB) according the manufacturer's recommendations. The labelled probe was purified by passage through a G-50 Quick Spin column (BMB).

The filters were incubated at 42°C for 16 hours with 5 x 10<sup>7</sup> counts per minute (cpm) of the probe, in 40-50 ml of a solution containing 50% formamide, 5X Denhardt's solution, 5X SSC (1X SSC is 0.15 M NaCl, 15 mM sodium citrate), 50 mM sodium phosphate, pH 6.5, and 0.1 mg/ml sheared salmon sperm DNA (Sigma, St. Louis MO). Following

- 22 -

hybridization, the filters were washed 3 times in 0.2X SSC and 0.2% SDS at 55°C for 30 minutes. To visualize hybridization, the washed filters were exposed overnight at -80°C on Kodak (Rochester, NY) XAR-5 autoradiographic film with Lightning-Plus intensifying screens (DuPont, DE).

- 5                   PCR was used to screen 50 of the hybridizing bacterial colonies. Fifty PCR reactions containing primers 390-1F and 390-2R were set up as described above, using bacteria from the fifty colonies in place of template DNA. Initially, the reactions were denatured at 94°C for 8 minutes. Thereafter, 35 cycles of amplification were carried out as described above.
- 10                  A single colony produced the expected 230 basepair product; the plasmid contained in this clone was designated pMP390-12.

- Additional MDC cDNAs of interest were identified by colony hybridization using a probe specific for the 5' end of the pMP390 insert. This probe was prepared as follows: a DNA fragment containing 211 bases of the
- 15                  coding region of the pMP390 cDNA (nucleotides 91-298 of SEQ. ID NO: 1) and 163 bases of the adjacent 3' non-coding region was generated by PCR as described above, using 60 ng of the pMP390 cDNA clone as template and synthetic oligonucleotides 390-1F (SEQ ID NO: 7) and 390-4R (SEQ ID NO: 9) as primers.

- 20                  390-4R: 5' AATGGATCCACAGCACGGAGGTGACCAAG 3'

Primer 390-4R contains a *Bam*H I restriction site followed by sequence complementary to nucleotides 461 to 442 of SEQ ID NO: 1.

- The PCR product was purified by electrophoresis as described above, and fifty ng of the purified fragment was labelled with the Random
- 25                  Primed DNA Labelling Kit (BMB) and purified by passage through a G-50 Quick Spin column (BMB). Filters were probed with this fragment as described above, and washed three times in 0.4 X SSC and 0.2 % SDS at



- 23 -

48°C for 30 minutes. Autoradiography was carried out as described above. Five hybridizing colonies were detected, designated MP390A, MP390B, MP390C, MP390D, and MP390E.

5        These five colonies and a colony transformed with pMP390-12 were isolated and grown for plasmid purification, using the Wizard Miniprep DNA Purification System (Promega, Madison, WI) with the addition of diatomaceous earth as described in Example 1. Plasmid DNA was sequenced on an Applied Biosystems Model 373 automated sequencer, using synthetic primer 390-3R (SEQ ID NO: 10):

10            390-3R: 5' AGTCAAGCTTAGGGCACTCTGGGATCGGCAC 3'.

Primer 390-3R is complementary to bases 266-246 of SEQ ID NO: 1, and contains a *Hind* III restriction endonuclease site and four additional base pairs at its 5' terminus. The primer was designed to anneal upstream of primer 390-2R and downstream of nucleotide 216 of SEQ ID NO: 1, the site at which  
15        an intron is predicted in the genomic DNA encoding the chemokine of the present invention [See Danoff *et al.*, *J. Immunology*, 152:1182-1189 (1994)].

Of the six clones, clones pMP390-12 and pMP390B contained the largest additional 5' coding sequence, each extending an additional 72 nucleotides upstream of the sequence previously obtained from the cDNA  
20        clone pMP390. A composite DNA sequence, herein designated MDC cDNA, was generated by alignment of the pMP390 and pMP390-12 cDNA sequences. This 2923 base pair composite cDNA sequence, and the deduced amino acid sequence of the chemokine MDC, are set forth in SEQ ID NOs: 1 and 2, respectively.

- 24 -

Manual comparison of the deduced MDC amino acid sequence with sequences of known chemokines indicates that the MDC cDNA sequence encodes a novel C-C chemokine ninety-three amino acids in length, sharing 28-34% amino acid identity with other C-C chemokines (Figure 1 and Table

5 1).

-25-

TABLE I  
Percent Identity Among Amino Acid Sequences of MDC  
and Previously Identified C-C Chemokines

	MDC	MCP-1	MCP-2	MCP-3	RANTES	MIP-1 $\alpha$	MIP-1 $\beta$	I-309
MDC		29%	28%	33%	34%	29%	33%	32%
MCP-1	29%		62%	72%	34%	38%	34%	33%
MCP-2	28%	62%		59%	30%	36%	33%	34%
MCP-3	33%	72%	59%		34%	35%	35%	37%
RANTES	34%	34%	30%	34%		50%	44%	22%
MIP-1 $\alpha$	29%	38%	36%	35%	50%		55%	35%
MIP-1 $\beta$	33%	34%	33%	35%	44%	55%		31%
I-309	32%	33%	34%	37%	22%	35%	31%	

- 26 -

Importantly, the four cysteine residues characteristic of the chemokines are conserved in MDC. Five additional residues also are completely conserved in the eight sequences presented in Fig. 1.

5 The first 24 amino acids of the 93 amino acid MDC sequence are predominantly hydrophobic and are consistent with von Heijne's rules [Nucleic Acids Res., 14: 4683-90 (1986)] governing signal cleavage. These features and the polypeptide comparison in Fig. 1 collectively suggest that the MDC cDNA encodes a twenty-four amino acid signal peptide that is cleaved to produce a mature form of MDC beginning with the glycine residue at  
10 position 1 of SEQ ID NO: 2. This prediction was confirmed by direct sequencing of MDC protein produced recombinantly in mammalian cells, as described below in Example 10. The MDC composite cDNA sequence shown in SEQ ID NO: 1 extends nineteen nucleotides upstream of the predicted initiating methionine codon, and 2.6 kb downstream of the termination codon.

15

### Example 3

#### Determination of MDC Gene Expression in Human Tissues

Northern blot analyses were conducted to determine the tissues in which the MDC gene is expressed.

20 The radiolabelled pMP390 5' fragment described in Example 2 (which corresponds to the region of the MDC cDNA encoding the putative mature form of MDC plus 163 bases of the adjacent 3' noncoding region) was used to probe Multiple Tissue Northern blots (Clontech, Palo Alto, CA) containing RNA from various normal human tissues. The probe was denatured by boiling prior to use, and the hybridizations were conducted  
25 according to the manufacturer's specifications. Autoradiographs were exposed 5 days at -80°C with 2 intensifying screens.

The greatest MDC gene expression was observed in the thymus, with much weaker expression detectable in spleen and lung tissues. Expression of MDC in tissue from the small intestine was at even lower

- 27 -

levels, and no expression was detected in brain, colon, heart, kidney, liver, ovary, pancreas, placenta, prostate, skeletal muscle, testis, or peripheral blood leukocytes.

#### Example 4

##### 5                   MDC Gene Expression During Macrophage Maturation

Because the cDNAs encoding MDC were isolated from a human macrophage cDNA library, MDC gene expression during differentiation of monocytes into macrophages was examined.

##### A.

10                   Human monocytes from a single donor were cultured on a series of tissue culture plates, and cells from one plate were harvested after 0, 2, 4 or 6 days. *See generally* Elstad *et al.*, *J. Immunol.* 140:1618-1624; Tjoelker *et al.*, *supra*. Under these conditions, the monocytes differentiated into macrophages by days 4-6 [Stafforini *et al.*, *J. Biol. Chem.*, 265: 9682-  
15 9687 (1990)].

A Northern blot of RNA (10  $\mu$ g per lane) isolated from the cells harvested at each time point was prepared and probed, using the radiolabelled pMP390 fragment as described above. No signal was detectable in RNA from freshly isolated monocytes, whereas a very strong  
20 signal was generated from cells that had differentiated into macrophages after six days of culture. Cells cultured for four days produced a much weaker signal, whereas the signal generated from cells cultured for two days could be seen only after prolonged exposure of the filter.

##### B.

25                   To confirm the expression of MDC in differentiated human macrophages, culture supernatants were analyzed by western blotting with anti-MDC monoclonal antibodies produced as described below in Example 18. Several plates of human macrophages were differentiated by growth on plastic

- 28 -

for eight days in the presence of macrophage colony stimulating factor (0.5 ng/ml, R&D Systems, Minneapolis, Minnesota).

The medium from the differentiated macrophage cell cultures was removed and replaced with similar medium or with medium containing

5 low density lipoprotein (LDL, Sigma), oxidized LDL (oxidized by incubation in 5  $\mu$ M CuSO<sub>4</sub>•5H<sub>2</sub>O according to the method of Malden *et al.*, *J. Biol. Chem.*, 266:13901 (1991)), or dexamethazone (6 nM, Sigma Chemical Co.). Following 3 days of each treatment, the culture medium was removed, brought to pH 6.8 by the addition of HCl, and passed over a Heparin-

10 Sepharose CL-6B column (Pharmacia, Piscataway, NJ). The column was washed with 0.2 M NaCl in 20 mM Tris, pH 8, and eluted with 0.6 M NaCl in 20 mM Tris, pH 8. The eluted material was fractionated on an 18% acrylamide SDS-PAGE gel (NOVEX) and electroblotted to PVDF membrane (Millipore, Bedford MA). The filter was blocked, washed, and reacted with

15 monoclonal antibodies against MDC using standard techniques (Sambrook *et al.*). In each of the culture media analyzed, MDC protein was detected at a concentration of approximately 0.5  $\mu$ g/ml, thus confirming expression of MDC in differentiated human macrophages.

Expression of MDC also was analyzed in human epithelial cell

20 lines. The colon epithelial cell line T84 (ATCC #CCL-248) was grown in DMEM/F12 medium (GIBCO, Gaithersburg MD), and the lung epithelial cell line A549 (ATCC #CCL-185) was grown in F12 medium. Screening for the presence of MDC mRNA in the cells and MDC protein in the culture medium was performed as described above for macrophages. No evidence of MDC

25 expression was detectable by either method in these cell lines.

In addition, samples of the T84 cell line were treated for 1 day with TNF $\alpha$  (5ng/ml, PeproTech, Rocky Hill, New Jersey), TGF- $\beta$  (1 ng/ml, R&D Systems), or interferon- $\gamma$  (200 U/ml, PeproTech), each with or without addition of recombinant MDC at 100 ng/ml (derived from CHO cell

30 transfectants; see Ex. 10). Samples of the A549 cell line were treated with

- 29 -

50 ng/ml PMA (Sigma Chemical Co.) for 0, 1, 3, 5, or 7 days. None of these treatments resulted in detectable expression of MDC mRNA in the T84 or A549 cells when screened by Northern blotting as described above.

### C.

5 Further examination of MDC gene expression in macrophages was conducted by treating the human cell line HL60 with either 1% DMSO (Sigma Chemical Co.) or 50 ng/ml PMA (Sigma). Treatment with DMSO induces differentiation of HL60 cells into a granulocytic cell type, whereas PMA induces their differentiation into a macrophage lineage [Perussia *et al.*,  
10 *Blood*, 58: 836-843 (1981)]. RNA was isolated from untreated cells and from cells treated for one or three days with DMSO or PMA, electrophoresed (10 $\mu$ g/lane), and blotted. The Northern blot of the RNA was probed with the radiolabelled pMP390 5' fragment described in Example 3.

15 After three days of PMA treatment, the HL-60 cells clearly expressed MDC mRNA, although the level of expression was apparently less than that of macrophages after six days of culture (see above). No expression was seen after one day of treatment or in untreated cells. Further, no detectable expression of MDC was induced by treatment with DMSO for one or three days.

20

### Example 5

#### In situ hybridization

Because MDC gene expression was detected in the thymus and spleen, *in situ* hybridization was carried out to localize the source of the message in these tissues. Further, *in situ* hybridization was used to correlate  
25 MDC gene expression to inflammation of intestinal tissue associated with Crohn's disease.

To generate radiolabelled *in situ* hybridization probes, a DNA fragment (nucleotides 91 to 301 of SEQ ID NO: 1) containing the MDC

- 30 -

coding region was subcloned into the vector pBluescript SK<sup>-</sup>. T3 and T7 RNA polymerases (BMB) were used according to the manufacturer's directions to incorporate <sup>35</sup>S-UTP into RNA transcripts complementary to each strand of the gene.

5                    Normal human spleen, thymus, and colon tissue samples, as well as colon tissue samples from patients with Crohn's disease, were obtained from the National Disease Research Interchange (Philadelphia, PA). The tissue donors were as follows: normal thymus: nineteen year old male Caucasian, death due to motor vehicle accident, tissue removed at autopsy;  
10                   normal spleen: 51 year old black male, death due to cerebral hemorrhage, tissue removed at autopsy; normal colon: black female, tissue removed during surgery; Crohn's colon #1: female, race not available, 46 years old, ulcerative colitis patient, tissue removed during surgery; Crohn's colon #2: eighteen  
15                   year old male, race not available, Crohn's disease patient, tissue removed during surgery.

                    In addition to the foregoing analyses, inflamed tonsil tissue that had been removed from a patient during tonsillectomy was probed with a non-coding portion of the MDC cDNA corresponding to nucleotides 677 to 1042 of SEQ ID NO: 1. This portion was generated by PCR amplification of the  
20                   MDC cDNA clone using the primers 390-7F (SEQ ID NO:26) and 390-8R (SEQ ID NO:27):

390-7F: 5'- TAT TGG ATC CGT TCT AGC TCC CTG TTC TCC 3'

390-8R: 5'- CCA AGA ATT CCT GCA GCC ACT TTC TGG GCT C 3'

25                   The fragment was cloned into pBluescript SK<sup>-</sup> vector for generation of RNA probes as described above.

                    The tissue samples described in the preceding paragraphs were prepared for *in situ* hybridization as follows. Tissue samples were imbedded in "OCT" compound (Miles, Inc., Elkhart, IN) and sectioned to a thickness



- 31 -

of 6 microns using a cryostat 2800E (Leica). The tissue sections were adhered to slides coated with Vectabond (Vector Laboratories, Burlingame, CA), fixed in 4% paraformaldehyde for 20 min. at 4 °C, dehydrated with ethanol, and denatured at 70°C with 70% formamide and 2X SSC.

5                   Hybridizations were performed by incubating the slides for 16 hours at 55°C with the radiolabelled sense or anti-sense strand of the appropriate probe in an aqueous hybridization solution containing 50% formamide, 0.3 M NaCl, 20 mM Tris pH 7.5, 10% dextran sulfate, 1X Denhardt's solution, 100 nM dithiothreitol, and 5 mM EDTA. After  
10 hybridization, the slides were incubated for one hour at room temperature in 4X SSC and 10 mM DTT. The slides were then washed at room temperature in 2X SSC; at 60°C in 1X SSC; and finally at room temperature in 0.1X SSC. Specimens were dehydrated in ethanol and then coated with Kodak NTB2 photographic emulsion, air-dried for 2 hours, exposed for 11 days at 4°C,  
15 developed, and counterstained with hematoxylin/eosin.

Observed hybridization of the anti-sense strand (of either probe) indicated that the MDC gene was expressed in cells throughout the cortex of normal human thymus, with weak signal in the follicles. Expression of MDC in the thymus may indicate a T lymphocyte developmental role of MDC.  
20 Expression in normal human spleen was localized to cells of the red pulp, whereas little signal was detected in the white pulp. A high level of expression in inflamed tonsil was localized to the epithelial region, although inflammatory cells appeared to have infiltrated the entire tissue sample.

Colon samples from patients with Crohn's disease exhibited  
25 hybridization in cells of the epithelium, lamina propria, Payer's patches, and smooth muscle. In contrast, normal human colon showed no hybridization above background. The observed pattern of MDC expression in the colons of Crohn's disease patients closely correlates with the expression of a macrophage-specific gene, Platelet Activating Factor Acetylhydrolase (PAF-  
30 AH) [Tjoelker *et al.*, *supra*]. This result, together with the data presented in

- 32 -

Example 4, suggest that macrophages express MDC cDNA *in vivo* during pathogenic inflammation. Moreover, the identification of MDC in Crohn's disease colon tissue samples suggest diagnostic relevance of MDC levels (*e.g.*, in a patient's blood, stool sample, and/or intestinal lesions) to a patient's disease state or clinical prognosis.

### Example 6

#### Production of recombinant MDC

To produce recombinant MDC protein, the sequence encoding the putative mature form of the protein was amplified by PCR and cloned into the vector pGEX-3X (Pharmacia, Piscataway, NJ). The pGEX vector is designed to produce a fusion protein comprising glutathione-S-transferase (GST), encoded by the vector, and a protein encoded by a DNA fragment inserted into the vector's cloning site.

The standard PCR conditions described in Example 2 were again employed to amplify an MDC cDNA fragment using the primers 390-2R and 390-FX2 (SEQ ID NO: 11):

5'TATCGGATCCTGGTTCGCGTGGCCCCTACGGCGCCAACATGGAA3'

Primer 390-FX2 contains a *Bam*H I restriction site, followed by a sequence encoding a thrombin cleavage site [Chang *et al.*, *Eur. J. Biochem.*, 151:217 (1985)] followed by bases 92-115 of SEQ ID NO: 1. The thrombin cleavage site is as follows: leucine-valine-proline-arginine-glycine-proline, in which glycine and proline are the first two residues of the mature form of MDC. Treatment of the recombinant fusion protein with thrombin is expected to cleave the arginine-glycine bond of the fusion protein, releasing the mature chemokine from the GST fusion.

The PCR product was purified by agarose gel electrophoresis, digested with *Bam*H I endonuclease, and cloned into the *Bam*H I site of

- 33 -

pGEX-3X. This pGEX-3X/MDC construct was transformed into *E. coli* XL-1 Blue cells (Stratagene, La Jolla CA), and individual transformants were isolated and grown. Plasmid DNA from individual transformants was purified and partially sequenced using an automated sequencer and primer GEX5 (SEQ ID NO: 12), which hybridizes to the pGEX-3X vector near the BamHI cloning site:

GEX5: 5' GAAATCCAGCAAGTATATAGCA 3'

The sequence obtained with this primer confirmed the presence of the desired MDC insert in the proper orientation.

Induction of the GST-MDC fusion protein was achieved by growing the transformed XL-1 Blue culture at 37°C in LB medium (supplemented with carbenicillin) to an optical density at wavelength 600 nm of 0.4, followed by further incubation for 4 hours in the presence of 0.25 to 1.0 mM Isopropyl  $\beta$ -D-Thiogalactopyranoside (Sigma Chemical Co., St. Louis MO).

The fusion protein, produced as an insoluble inclusion body in the bacteria, was purified as follows. Cells were harvested by centrifugation; washed in 0.15 M NaCl, 10 mM Tris, pH 8, 1 mM EDTA; and treated with 0.1 mg/ml lysozyme (Sigma Chemical Co.) for 15 minutes at room temperature. The lysate was cleared by sonication, and cell debris was pelleted by centrifugation for 10 minutes at 12,000 X g. The fusion protein-containing pellet was resuspended in 50 mM Tris, pH 8, and 10 mM EDTA, layered over 50% glycerol, and centrifuged for 30 min. at 6000 X g. The pellet was resuspended in standard phosphate buffered saline solution (PBS) free of  $Mg^{++}$  and  $Ca^{++}$ . The fusion protein, which remained insoluble, was approximately 80-90% of the protein mass and migrated in denaturing SDS-polyacrylamide gels with a relative molecular weight of 33 kD. The protein

- 34 -

yield, as judged by Coomassie staining, was approximately 100 mg/l of *E. coli* culture.

The fusion protein was subjected to thrombin digestion to cleave the GST from the mature MDC protein. The digestion reaction (20-40 ug fusion protein, 20-30 units human thrombin (4000 U/ mg (Sigma) in 0.5 ml PBS) was incubated 16-48 hrs. at room temperature and loaded on a denaturing SDS-PAGE gel to fractionate the reaction products. The gel was soaked in 0.4 M KCl to visualize the GST and MDC protein bands, which migrated as fragments of approximately 26 kD and 7 kD, respectively.

The identity of the 7 kD SDS-PAGE fragment was confirmed by partial amino acid sequence analysis. First, the protein was excised from the gel, electroeluted in 25 mM Tris base and 20 mM glycine, and collected onto a PVDF membrane in a ProSpin column (Applied Biosystems, Foster City, CA). Subjecting the sample to automated sequencing (Applied Biosystems Model 473A, Foster City, CA) yielded 15 residues of sequence information, which corresponded exactly to the expected N-terminus of the predicted mature form of MDC (SEQ ID NO: 2, amino acid residues 1 to 15).

#### Example 7

##### Construction of a Bacterial MDC Expression Vector

The portion of the MDC cDNA encoding the predicted mature MDC protein was cloned into a plasmid containing the arabinose promoter and the *pelB* leader sequence [see Better *et al.*, *Science*, 240:1041-43 (1988)].

More particularly, an MDC cDNA was amplified by PCR as described in Example 2, using approximately 0.1  $\mu$ g of pMP390-12 as template and synthetic oligonucleotide primers 390-2R and 390-Pel (SEQ ID NO: 13):

390-Pel: 5 'ATTGCCATGGCCGGCCCCCTACGGCGCCAACATGGAA 3'

- 35 -

Primer 390-Pel contains an *Nco* I restriction site, followed by two cytosine residues, followed by bases 92 to 115 of SEQ ID NO: 1.

The expected PCR product of 232 bp was purified by agarose gel electrophoresis, digested with *Nco* I and *Bam*H I, and cloned along with  
5 a portion of the arabinose operon and *pelB* leader sequence (Better et al.,  
*supra*) into the vector pUC19 (New England Biolabs, Beverly, MA). The  
resultant construct, designated P2-390, encodes a fusion of the *pelB* leader  
(encoded by the vector) to the mature MDC protein. The sequence of this  
construct was confirmed by automated sequencing using the primers Ara1  
10 (SEQ ID NO:28) and Ara2 (SEQ ID NO:29), which anneal to the vector  
adjacent to the cloning site.

Ara1: 5' GCG ACT CTC TAC TGT TTC TC3'

Ara2: 5'-CAC AGG AAA CAG CTA TGA CC3'

The plasmid P2-390 was transformed into the *E. coli* strain MC1061 using  
15 standard procedures, and an ampicillin resistant clone was selected for MDC  
production. The clone was grown in a 3 liter fermenter (Applikon, Foster  
City, CA) and MDC production was induced by the addition of 50% arabinose  
to a final concentration of 0.1%. After one day of incubation in the presence  
of arabinose, the cells were harvested. Western blotting revealed that MDC  
20 was present within the cells at a level of approximately 4 µg/g of cell paste  
and was secreted into the culture medium to a level of approximately 1 µg/ml.

### Example 8

#### Purification of Recombinant MDC from Bacteria and Culture Medium

Following is an experimental protocol for purification of the  
25 recombinant MDC produced as described in Example 7.

- 36 -

The secreted recombinant MDC protein is purified from the bacterial culture media by, *e.g.*, adapting methods previously described for the purification of recombinantly produced RANTES chemokine [Kuna *et al.*, *J. Immunol.*, 149:636-642 (1992)], MGSA chemokine [Horuk *et al.*, *J. Biol. Chem.* 268:541-46 (1993)], and IP-10 chemokine (expressed in insect cells) [Sarris *et al.*, *J. Exp. Med.*, 178:1127-1132 (1993)].

### Example 9

#### Recombinant Production of MDC in Yeast

Following are protocols for the recombinant expression of MDC in yeast and for the purification of the recombinant MDC.

The coding region of the MDC cDNA is amplified from pMP390-12 by PCR, using as primers synthetic oligonucleotides containing the MDC cDNA sequences present in primers 390-1F and 390-2R. A DNA encoding the yeast pre-pro-alpha leader sequence is amplified from yeast genomic DNA in a PCR reaction using one primer containing bases 1-20 of the alpha mating factor gene and another primer complimentary to bases 255-235 of this gene [Kurjan and Herskowitz, *Cell*, 30:933-943 (1982)]. The pre-pro-alpha leader coding sequence and MDC coding sequence fragments are ligated into a plasmid containing the yeast alcohol dehydrogenase (ADH2) promoter, such that the promoter directs expression of a fusion protein consisting of the pre-pro-alpha factor fused to the mature MDC polypeptide. As taught by Rose and Broach, *Meth. Enz.* 185:234-279, D. Goeddel, ed., Academic Press, Inc., San Diego, CA (1990), the vector further includes an ADH2 transcription terminator downstream of the cloning site, the yeast "2-micron" replication origin, the yeast leu-2d gene, the yeast REP1 and REP2 genes, the *E. coli* beta-lactamase gene, and an *E. coli* origin of replication. The beta-lactamase and leu-2d genes provide for selection in bacteria and yeast, respectively. The leu-2d gene also facilitates increased copy number of the plasmid in yeast to induce higher levels of expression. The REP1 and

- 37 -

REP2 genes encode proteins involved in regulation of the plasmid copy number.

The DNA construct described in the preceding paragraph is transformed into yeast cells using a known method, *e.g.*, lithium acetate treatment [Stearns *et al.*, *Meth. Enz.*, *supra*, pp. 280-297]. The ADH2 promoter is induced upon exhaustion of glucose in the growth media [Price *et al.*, *Gene*, 55:287 (1987)]. The pre-pro-alpha sequence effects secretion of the fusion protein from the cells. Concomitantly, the yeast KEX2 protein cleaves the pre-pro sequence from the mature MDC chemokine [Bitter *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:5330-5334 (1984)].

Alternatively, MDC is recombinantly expressed in yeast using a commercially available expression system, *e.g.*, the Pichia Expression System (Invitrogen, San Diego, CA), following the manufacturer's instructions. This system also relies on the pre-pro-alpha sequence to direct secretion, but transcription of the insert is driven by the alcohol oxidase (AOX1) promoter upon induction by methanol.

The secreted MDC is purified from the yeast growth medium by, *e.g.*, the methods used to purify MDC from bacterial and mammalian cell supernatants (see Examples 8 and 10).

20

### Example 10

#### Recombinant Production of MDC in Mammalian Cells

MDC was recombinantly produced in mammalian cells according to the following procedures.

##### A. Synthesis of Expression Vector 390HXE

25

A truncated version of the MDC cDNA was synthesized by PCR as described in Example 2, using pMP390-12 as template and the synthetic oligonucleotides 390RcH and 390RcX as primers.

- 38 -

(SEQ ID NO: 14)

390RcH: 5'GACCAAGCTTGAGACATACAGGACAGAGCA

~~(SEQ ID NO: 15)~~

390RcX: 5'TGGATCTAGAAGTTGGCACAGGCTTCTGG

- 5 Primer 390RcH contains a *Hind* III restriction site followed by bases 1 to 20 of SEQ ID NO: 1; primer 390RcX contains an *Xba* I restriction site followed by the sequence complimentary to bases 403 to 385 of SEQ ID NO: 1.

- 10 The expected 423 bp PCR product was purified by agarose gel electrophoresis and cloned into *Hind* III/*Xba* I-digested pRc/CMV ((In Vitrogen, San Diego CA) a vector which allows for direct expression in mammalian cells). The resulting plasmid, designated 390HmX, contained bases 1 to 403 of SEQ ID NO: 1. The sequence of the insert was confirmed by automated sequencing using the primers DC03 (SEQ ID NO: 16) and JHSP6.

- 15 DC03: 5' CGA AAT TAA TAC GAC TCA CT 3'

Primer DC03 anneals to the pRc/CMV vector sequence adjacent to the cloning site.

B. Synthesis of Expression Vector 390HmX

- 20 Another MDC cDNA construct was generated by PCR, using pMP390-12 as template and the primers 390RcH and 390mycRX (SEQ ID NO: 17).

390mycRX: 5' TGGATCTAGATCAATTCAAGTCCTCCTCGCT  
GATCAGCTTCTGCTCTTGGCTCAGCTTATTGAGAAT 3'



- 39 -

Primer 390mycRX contains an *Xba* I restriction site, a sequence complementary to the sequence encoding a "myc" epitope [Fowlkes *et al.*, *BioTechniques*, 13:422-427 (1992)], and a sequence complementary to bases 298 to 278 of SEQ ID NO: 1. This reaction amplified the expected 354 bp  
5 fragment containing bases 1 to 298 of SEQ ID NO: 1 fused to a "myc" epitope at the MDC carboxy-terminus. This epitope can be used to facilitate immunoprecipitation, affinity purification, and detection of the MDC-myc fusion protein by Western blotting. The fragment was cloned into pRc/CMV to generate the plasmid 390HmX. The sequence of the insert was confirmed  
10 by automated sequencing using the primer DC03.

C. Expression of MDC in 293T and NS0 Cells

Two transfection protocols were used to express the two MDC cDNA constructs described above in subparts A. and B.: transient transfection into the human embryonic kidney cell line 293T and stable  
15 transfection into the mouse myeloma cell line NS0 (ECACC 85110503).

Transient transfection of 293T cells was carried out by the calcium phosphate precipitation protocol of Chen and Okayama, *BioTechniques*, 6:632-638 (1988) and *Mol. Cel. Biol.*, 87:2745-2752 (1987). Cells and supernatants were harvested four days after transfection. A  
20 Northern blot was prepared from 4  $\mu$ g of total RNA from each cell lysate and probed with a radiolabelled MDC fragment prepared by PCR. The template for the labelling reaction was the PCR fragment previously generated by amplifying pMP390 with the primers 390-1F and 390-4R (see Example 2). Approximately 30 ng of this fragment was employed in a PCR reaction  
25 containing the following: 1.5 mM  $MgCl_2$ , 50 mM KCl, 10 mM Tris, pH 8.4, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dGTP, 1  $\mu$ M dCTP, 50  $\mu$ Ci  $\alpha^{32}P$ -dCTP (DuPont/New England Nuclear, Boston MA), 2.5 U Taq polymerase, and 10  $\mu$ g/ml each of primers 390-1F and 390-2R. The reaction was denatured by heating for 4 minutes at 94°C, followed by 15 cycles of  
30 amplification as described in Example 2. The probe was purified by passage

- 40 -

over a G-25 Quick Spin column (BMB). Conditions for hybridization were described in Example 2. Filters were subsequently washed in 0.5 X SSC and 0.2% SDS at 42°C for 30 minutes. Autoradiography was carried out at -80°C with one intensifying screen for sixteen hours. The MDC DNA constructs  
5 were very highly expressed in the transfected cells and not detectable in the non-transfected cells.

For stable transfections, NS0 cells were grown to 80% confluency in D-MEM (Gibco), collected by centrifugation, and washed with PBS. Twenty µg of plasmid DNA was linearized with *Sca* I restriction  
10 endonuclease (BMB), added to the cells, and incubated on ice for 15 minutes in a 0.4 cm gap cuvette (BioRad, Hercules CA). The cells were electroporated with two pulses of 3 microfarad at 1.5 kilovolts. Cells were diluted into 20 ml D-MEM, incubated at 37°C in 5% CO<sub>2</sub> for 24 hours, and selected by plating into 96-well plates at various dilutions in D-MEM  
15 containing 800 µg/ml geneticin. Wells containing single drug-resistant colonies were expanded in selective media. Total RNA was analyzed by Northern blotting as described in the preceding paragraph. Message for MDC was seen only in transfected cell lines.

MDC is purified from mammalian culture supernatants by, *e.g.*,  
20 adapting methods described for the purification of recombinant TCA3 chemokine [Wilson *et al.*, *J. Immunol.*, 145:2745-2750 (1990)], or as described below in subpart F.

#### D. Expression of MDC in CHO Cells

PCR was used to amplify bases 1 to 403 of the MDC cDNA  
25 clone using primers 390RcH and 390RcX (SEQ. ID NOs: 14 and 15), as described above in subpart A. The fragment was cloned into the HindIII and XbaI sites of the expression vector pDC1, a pUC19 derivative that contains the cytomegalovirus (CMV) promoter to drive expression of the insert. More specifically, vector pDC1, depicted in Figure 8, was derived from pRc/CMV  
30 and pSV2-dhfr (ATCC vector #37146). Vector pDC1 is similar to the

- 41 -

mammalian expression vector pRc/CMV (Invitrogen, San Diego) except that pDC1 carries the mouse dihydrofolate reductase (dhfr) gene as a selectable marker, in place of the neomycin phosphotransferase gene. Transcription of the target gene in pDC1 is under the control of the strong CMV promoter.

5 See Stenberg *et al.*, *J. Virology*, 49:190-199 (1984). Additionally, a polyadenylation sequence from the bovine growth hormone gene [Goodwin and Rottman, *J. Biol. Chem.*, 267:16330-16334 (1992)] is provided on the 3' side of the target gene. The dhfr expression cassette [Subramani *et al.*, *Mol. Cell. Biol.* 1:854-864 (1981)] allows selection for pDC1 in cells lacking a

10 functional dhfr gene.

XL-1 Blue bacteria (Stratagene) were transformed with the pDC1/MDC plasmid using standard techniques of CaCl<sub>2</sub> incubation and heat shock (Sambrook *et al.*). Transformants were grown in LB medium containing 100 µg/ml carbenicillin. Plasmid DNA from individual

15 transformed clones was isolated using the Promega Wizard Maxiprep system (Madison, WI) and its sequence was confirmed by automated sequencing using the primers 390-IF and 390-2R. The plasmid was linearized by restriction digestion with PvuI endonuclease (Boehringer Mannheim), which cuts once within the vector sequence.

20 The Chinese hamster ovary (CHO) cell line used for production of MDC was DG-44, which was derived by deleting the dhfr gene. See Urlaub *et al.*, *Cell*, 33:405 (1983). For electroporation, 10<sup>7</sup> of these CHO cells were washed in PBS, resuspended in 1 ml PBS, mixed with 25 µg of linearized plasmid, and transferred to a 0.4 cm cuvette. The suspension was

25 electroporated with a Biorad Gene Pulser (Richmond, CA) at 290 volts, 960 µFarad. Transfectants were selected by growth in  $\alpha$  medium (Cat. No. 12000, Gibco, Gaithersburg, MD) containing 10% dialyzed fetal bovine serum (FBS) (Hyclone, Logan, UT) and lacking hypoxanthine and thymidine. Cells from several hundred transfected colonies were pooled and re-plated in  $\alpha$

30 medium containing 20 nM methotrexate (Sigma, St. Louis, MO). Colonies

- 42 -

surviving this round of selection were isolated and expanded in  $\alpha$  medium containing 20 nM methotrexate.

E. Purification of MDC for protein sequencing

- Transfected CHO clones were grown on plastic tissue culture dishes to approximately 90% confluence in  $\alpha$  medium, at which time the medium was replaced with P5 medium containing 0.2% to 1.0% FBS. P5 medium consists of the components listed in Table 2, below (purchased as a premixed powder form Hyclone, Logan UT), supplemented with the following additional components:
- 10           (1)    3 g/l sodium bicarbonate (Sigma, St. Louis, MO);
  - (2)    2  $\mu$ g/l sodium selenite (Sigma);
  - (3)    1% soy bean hydrolysate (Quest International, Naarden, The Netherlands);
  - (4)    1x ferrous sulfate/EDTA solution (Sigma);
  - 15           (5)    1.45 ml/l EX-CYTE VLE solution (Bayer, Kankakee, IL);
  - (6)    10  $\mu$ g/ml recombinant insulin (Nucellin, Eli Lilly, Indianapolis, IN);
  - (7)    0.1% pluronic F-68 (Sigma);
  - (8)    30  $\mu$ g/ml glycine (Sigma);
  - 20           (9)    50  $\mu$ M ethanolamine (Sigma); and
  - (10)   1 mM sodium pyruvate (Sigma).

- 43 -

TABLE 2		
	Component	Powder #5 gm/L
INORGANIC SALTS	Sodium Chloride	4.0
	Potassium Chloride	0.4
	Sodium Phosphate Dibasic, Anhydrous	0.07102
	Sodium Phosphate Monobasic H <sub>2</sub> O	0.0625
	Magnesium Sulfate, Anhydrous	0.1
	Cupric sulfate 5 H <sub>2</sub> O	0.00000125
	Ferrous Sulfate 7 H <sub>2</sub> O	0.000417
	Zinc Sulfate 7 H <sub>2</sub> O	0.0004315
	Ferric Nitrate 9 H <sub>2</sub> O	0.00005
	Calcium Chloride, Anhydrous	0.11661
	Magnesium Chloride, Anhydrous	0
AMINO ACIDS	L-Alanine	0
	L-Arginine HCl	0.15
	L-Asparagine H <sub>2</sub> O	0.075
	L-Aspartic Acid	0.04
	L-Cysteine HCl H <sub>2</sub> O	0.035
	L-Cystine 2 HCl	0.12
	L-Glutamic Acid	0.02
	L-Glutamine	0.5846
	Glycine	0.02
	L-Histidine HCl H <sub>2</sub> O	0.04
	L-Isoleucine	0.15
	L-Leucine	0.15
	L-Lysine HCl	0.1

- 44 -

	L-Methionine	0.05
	L-Proline	0.05
	L-Phenylalanine	0.05
	L-Serine	0.075
	L-Threonine	0.075
	L-Tryptophan	0.02
	L-Tyrosine 2 Na 2 H <sub>2</sub> O	0.075
	L-Valine	0.125
VITAMINS	Biotin	0.001
	D-Calcium Pantothenate	0.0025
	Choline Chloride	0.015
	Folic Acid	0.005
	i-Inositol	0.175
	Nicotinamide	0.005
	Pyridoxal HCl	0.005
	Pyridoxine HCl	0.005
	Riboflavin	0.001
	Thiamine HCl	0.005
	Cyanocobalamine	0.001
OTHER	D-Glucose	1.0
	Hypoxanthine, Na	0.005
	Thymidine	0.005
	Putrescine 2HCl	0.000081
	Sodium Pyruvate	0.11004
	Linoleic Acid	0.0001
	DL-Alpha-Lipoic Acid	0.0002
	Phenol Red, Na Salt	0.0086022

- 45 -

After two additional days in culture, an aliquot of each supernatant was mixed with an equal volume of acetone. The precipitated proteins were pelleted by centrifugation, fractionated on an 18% Tris Glycine gel (NOVEX), and blotted to a PVDF membrane (Millipore, Bedford, MA).

5 MDC bound to the membrane was detected by a crude preparation of monoclonal antibody to MDC (prepared as described in Example 18). Cells from the clone secreting the highest level of MDC protein (approx. 1  $\mu$ g/ml) were removed from the plate by treatment with a solution of 0.5% trypsin and 5.3 mM EDTA (GIBCO) and used to start a suspension  
10 culture in  $\alpha$  medium plus 10% fetal bovine serum (FBS). Over the course of 8 days, 5 volumes of P5 medium were added to the culture. Proteins were precipitated from the culture supernatant by addition of polyethylene glycol (MW 8000, Union Carbide, Danbury, CT) to 20 % (weight/volume), fractionated on an 18% Tris glycine gel, and electroblotted to a PVDF  
15 membrane (Millipore, Bedford, MA) in CAPS buffer (3-[Cyclohexylamino]-1-propanesulfonic acid, pH 10.4) (Sigma, St. Louis, MO). A strip of the filter was removed for detection of MDC by western blotting with the supernatant from a hybridoma cell line producing anti-MDC monoclonal antibodies (See Example 18). The reactive band, which migrated with an apparent molecular  
20 weight of 6.4 kD, was excised from the remaining portion of the filter.

Using an automated sequencer (Applied Biosystems, Model 473A, Foster City, CA), the sequence of the N-terminus of the protein was determined to be: GPYGANMEDS. This sequence is identical to that of residues 1 to 10 of SEQ ID NO. 2, corresponding to the N-terminus of the  
25 predicted mature form of MDC.

#### F. Purification of MDC for biological assays

For growth of larger cultures, MDC-expressing CHO cells were grown to 80% confluence on tissue culture plates in  $\alpha$  medium. The cells were removed from the plates by treatment with trypsin and EDTA and  
30 resuspended at a density of  $3 \times 10^5$  cells/ml in P5 medium plus 1% FBS in a

- 46 -

spinner flask at 37 °C. Additional P5/1% FBS medium was added as needed to keep the cell density in the range of  $1 \times 10^6$  to  $3 \times 10^6$ .

After 11 days in culture, the cells were removed from the medium by filtration. The pH of the culture medium was adjusted to 6.8, and  
5 it was passed over a heparin-Sepharose CL-6B column (Pharmacia, Piscataway, NJ). After washing with 0.2 M NaCl in potassium phosphate buffer, pH 7, the column was eluted with a linear gradient of 0.2 to 0.7 M NaCl. Fractions were analyzed by SDS-PAGE and Coomassie stained to determine which of them contained MDC. MDC eluted from the column at  
10 approximately 0.6 M NaCl.

The fractions containing MDC were pooled and concentrated by ultrafiltration in stirred-cell chamber (Amicon, Beverly, MA) using a filter with a MW cutoff of 3 kD. Octylglucoside (10 mM final concentration, Boehringer Mannheim Biochemicals) was added to the concentrated MDC,  
15 which subsequently was passed through a Sephacryl HR100 column (Pharmacia, Piscataway, NJ). Fractions were analyzed by SDS-PAGE for the presence of MDC. The final yield of MDC protein was approximately 0.1 mg/liter of culture supernatant, and the purity was estimated to be greater than 95%, as judged by Coomassie staining.

20

### Example 11

#### Production of MDC and MDC Analogs by Peptide Synthesis

MDC and MDC polypeptide analogs are prepared by chemical peptide synthesis using techniques that have been used successfully for the production of other chemokines such as IL-8 [Clark-Lewis *et al.*, *J. Biol*  
25 *Chem.*, 266:23128-34 (1991)] and MCP-1. Such methods are advantageous because they are rapid, reliable for short sequences such as chemokines, and enable the selective introduction of novel, unnatural amino acids and other chemical modifications.



- 47 -

For example, MDC and MDC analogs were chemically synthesized using optimized stepwise solid-phase methods [Schnolzer *et al.*, *Int. J. Pept. Protein Res.*, 40:180 (1992)] based on *t*-butyloxycarbonyl (Boc) chemistries of Merrifield [*J. Am. Chem. Soc.*, 85:2149-2154 (1963)] on an  
5 Applied Biosystems 430A Peptide Synthesizer (Foster City, CA). The proteins were purified by reverse-phase HPLC and characterized by standard methods, including electrospray mass spectrometry and nuclear magnetic resonance.

The chemically synthesized MDC corresponded to the mature  
10 form of recombinant MDC, consisting of residues 1 to 69 of SEQ ID NO. 2. Several methods were used to compare the chemically synthesized MDC to the recombinant MDC produced by CHO cell transfectants as described in Example 10. The migration of chemically synthesized MDC was identical to that of the recombinant MDC in denaturing SDS-PAGE (18% Tris glycine  
15 gel, NOVEX). In addition, the proteins reacted similarly in western blot analyses using monoclonal and polyclonal antibodies raised against bacterially produced MDC as described below in Example 18. The chemically synthesized MDC also appeared to behave in the same manner as the recombinant MDC in immunoprecipitation assays with the anti-MDC  
20 monoclonal antibodies. These studies indicate that the denatured and the non-denatured structures of chemically synthesized MDC are similar to those of recombinant MDC.

The following MDC analogs also have been chemically synthesized:

- 25 1) "MDC (n+1)" (SEQ ID NO: 30) consists of Leucine followed by residues 1 to 69 of SEQ ID NO. 2.
2. "MDC (9-69)" consists of residues 9 to 69 of SEQ ID NO. 2.
3. "MDC-yl" (SEQ ID NO: 31) consists of residues 1 to 69 of SEQ ID NO. 2, with the following substitution: Residues 59-60 (Trp-Val)  
30 were replaced with the sequence Tyr-Leu.

- 48 -

4. "MDC-eyfy" (SEQ ID NO: 32) consists of residues 1 to 69 of SEQ ID NO. 2, with the following substitution: Residues 28-31 (His-Phe-Tyr-Trp) were replaced with the sequence Glu-Tyr-Phe-Tyr, derived from the amino acid sequence of the chemokine RANTES (residues 26-29 of SEQ ID NO: 21).

5 The analogs "MDC (n+1)", "MDC (9-69)", and "MDC-yl" are expected to be antagonists of MDC activity, inhibiting MDC activity by competitively binding to the same receptor that recognizes MDC. Alternatively, they may effect inhibition by forming heterodimers with the native MDC. Possible activities of the analog "MDC-eyfy" include inhibition of MDC as described for the previous analogs. In contrast, "MDC-eyfy" may behave similar to native MDC. Other activities of this analog may include functions typical of the chemokine RANTES, such as chemotaxis of T lymphocytes, monocytes, or eosinophils.

15 Additionally, the following single-amino acid alterations (alone or in combination) are specifically contemplated: (1) substitution of a non-basic amino acid for the basic arginine and/or lysine amino acids at positions 24 and 27, respectively, of SEQ ID NO: 2; (2) substitution of a charged or polar amino acid (e.g., serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine or cysteine) for the tyrosine amino acid at position 30 of SEQ ID NO: 2, the tryptophan amino acid at position 59 of SEQ ID NO: 2, and/or the valine amino acid at position 60 of SEQ ID NO: 2; and (3) substitution of a basic or small, non-charged amino acid (e.g., lysine, arginine, histidine, glycine, alanine) for the glutamic acid amino acid at position 50 of SEQ ID NO: 2. Specific analogs having these amino acid alterations are encompassed by the following formula (SEQ ID NO: 25):

Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val Leu Val Leu Leu Ala  
-24 -20 -15 -10

30 Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu  
-5 1 5

- 49 -

	Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	Arg	Leu	Pro	Leu	Xaa
	10						15					20				
	Val	Val	Xaa	His	Phe	Xaa	Trp	Thr	Ser	Asp	Ser	Cys	Pro	Arg	Pro	Gly
	25					30				35					40	
5	Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Xaa	Ile	Cys	Ala	Asp	Pro	Arg
					45					50					55	
	Val	Pro	Xaa	Xaa	Lys	Met	Ile	Leu	Asn	Lys	Leu	Ser	Gln			
					60					65						

wherein the amino acid at position 24 is selected from the group consisting of arginine, glycine, alanine, valine, leucine, isoleucine, proline, serine, threonine, phenylalanine, tyrosine, tryptophan, aspartate, glutamate, asparagine, glutamine, cysteine, and methionine; wherein the amino acid at position 27 is independently selected from the group consisting of lysine, glycine, alanine, valine, leucine, isoleucine, proline, serine, threonine, phenylalanine, tyrosine, tryptophan, aspartate, glutamate, asparagine, glutamine, cysteine, and methionine; wherein the amino acid at position 30 is independently selected from the group consisting of tyrosine, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, and cysteine; wherein the amino acid at position 50 is independently selected from the group consisting of glutamic acid, lysine, arginine, histidine, glycine, and alanine; wherein the amino acid at position 59 is independently selected from the group consisting of tryptophan, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, and cysteine; and wherein the amino acid at position 60 is independently selected from the group consisting of valine, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, and cysteine. Such MDC polypeptide analogs are specifically contemplated to modulate the binding characteristics of MDC to chemokine receptors and/or other molecules (e.g., heparin, glycosaminoglycans, erythrocyte chemokine receptors) that are considered to be important in presenting MDC to its receptor.

- 50 -

Recombinant techniques such as those described in the preceding examples also are contemplated for preparing MDC polypeptide analogs. More particularly, polynucleotides encoding MDC are modified to encode polypeptide analogs of interest using well-known techniques, e.g., site-directed mutagenesis and the polymerase chain reaction. See generally Sambrook *et al.*, *supra*, Chapter 15. The modified polynucleotides are expressed recombinantly, and the recombinant MDC polypeptide analogs are purified, as described in the preceding examples.

The chemoattractant and/or cell-activation properties of MDC or MDC polypeptide analogs on one or more types of cells involved in the inflammatory process, (e.g., T lymphocytes, monocytes, macrophages, basophils, eosinophils, neutrophils, mast cells, endothelial cells, epithelial cells, fibroblasts, or others) are assayed by art-recognized techniques that have been used for numerous other chemokines. Native MDC, recombinant MDC or MDC polypeptide analogs, or synthetic MDC or MDC polypeptide analogs purified and isolated as described in one or more of the preceding examples are assayed for activity as described in the following examples with respect to MDC.

#### Example 12

##### Assay of MDC Effects upon Basophils, Mast Cells, and Eosinophils

The effect of MDC upon basophils, mast cells, and eosinophils is assayed, e.g., by methods described by Weber *et al.*, *J. Immunol.*, 154:4166-4172 (1995) for the assay of MCP-1/2/3 activities. In these methods, changes in free cytosolic calcium and release of proinflammatory mediators (such as histamine and leukotriene) are measured. Blocking chemokine-mediated activation of these cell types has implications in the treatment of late-phase allergic reactions, in which secretion of proinflammatory mediators plays a significant role [Weber *et al.*, *supra*].

- 51 -

**Example 13****Assay of Chemoattractant and Cell-Activation  
Properties of MDC upon Human  
Monocytes/Macrophages and Human Neutrophils**

5           The effects of MDC upon human monocytes/macrophages or human neutrophils is evaluated, *e.g.*, by methods described by Devi *et al.*, *J. Immunol.*, 153:5376-5383 (1995) for evaluating murine TCA3-induced activation of neutrophils and macrophages. Indices of activation measured in such studies include increased adhesion to fibrinogen due to integrin  
10 activation, chemotaxis, induction of reactive nitrogen intermediates, respiratory burst (superoxide and hydrogen peroxide production), and exocytosis of lysozyme and elastase in the presence of cytochalasin B. As discussed by Devi *et al.*, these activities correlate to several stages of the leukocyte response to inflammation. This leukocyte response, reviewed by  
15 Springer, *Cell*, 76:301-314 (1994), involves adherence of leukocytes to endothelial cells of blood vessels, migration through the endothelial layer, chemotaxis toward a source of chemokines, and site-specific release of inflammatory mediators. The involvement of MDC at any one of these stages provides an important target for clinical intervention, for modulating the  
20 inflammatory response.

          In one art-recognized chemotaxis assay, a modified Boyden chamber assay, leukocytes to be tested are fluorescently labeled with calcein by incubating for 20 minutes at room temperature. The labeled cells are washed twice with serum-free RPMI, resuspended in RPMI containing 2  
25 mg/ml of BSA, and then added quantitatively to the upper wells of the chambers, which are separated from the lower wells by a polycarbonate filter (Neuroprobe Inc. Cabin John, MD). MDC diluted in the same medium as the leukocytes is added to the lower wells at various concentrations. Chambers are incubated for 2 hours at 37 °C. At the end of the assay, cells that have  
30 not migrated through the membrane are removed by rinsing the filter with PBS and scraping with a rubber policeman. Cells that have migrated through

- 52 -

the filter are quantitated by reading fluorescence per well in a fluorescent plate reader (Cytofluor, Millipore Inc., Boston, MA).

A series of experiments were performed using art-recognized procedures to determine the chemotactic properties of MDC. Initially, the response of human mononuclear cells to MDC was determined. The effect of MDC on the chemotactic response of polymorphonuclear leukocytes (granulocytes) also was examined.

It has been established that MCP-1, which is a C-C chemokine, causes both recruitment and activation of monocytes but appears to have limited ability to induce the migration of macrophages. The failure of MCP-1 to attract macrophages appears to be correlated to the differentiation process: as monocytic cells differentiate, there is a progressive decrease in cell response to MCP-1 [Denholm and Stankus, *Cytokine*, 7: 436-440 (1995)]. The biological activities of MCP-1 appear to correlate with the expression of this chemokine, with MCP-1 mRNA being found in monocytes but decreasing as these cells differentiate.

The pattern of expression of MDC appears to be the reverse of that described for MCP-1, with the amount of mRNA for MDC increasing as monocytes differentiate to macrophages. To determine whether this expression pattern correlates to the biological response to MDC, the effects of MDC on the migration of monocytes and macrophages were compared.

A number of different leukocyte cells types were analyzed in chemotaxis and chemotaxis inhibition assays. Human mononuclear and polymorphonuclear leukocytes were isolated from peripheral blood using methods known in the art [Denholm *et al.*, *Amer. J. Pathol.*, 135:571-580 (1989)]. Second, the human monocytic cell line, THP-1 (obtained from the ATCC, Rockville, MD, and maintained in culture in RPMI with 10% FBS and with penicillin/streptomycin) was employed. THP-1 cells can be cultured as monocytes or can be induced to differentiate to macrophages by treatment with phorbol myristate acetate (PMA) [Denholm and Stankus,

- 53 -

*Cytokine*, 7:436-440 (1995)]. In some experiments monocytic THP-1 cells were employed, and in others monocytic THP-1 cells were differentiated to macrophages by incubation with phorbol myristate acetate (PMA). Third, guinea pig peritoneal macrophages were obtained essentially as described in  
5 Yoshimura, *J. Immunol.*, 150:5025-5032 (1993). Briefly, animals were given an intraperitoneal injection of 3% sterile thioglycollate (DIFCO) two days prior to cell harvest. Macrophages were obtained from the peritoneal cavity by lavage with phosphate buffered saline (PBS) with 1 mM EDTA and 0.1% glucose. Cells were washed once by centrifugation and then utilized in  
10 chemotaxis assays as described below.

Assays of chemotactic activity were carried out, using the cell preparations described above, essentially as described by Denholm and Stankuş, *Cytometry*, 19:366-369 (1995), using 96-well chambers (Neuroprobe Inc., Cabin John, MD) and cells labeled with the fluorescent dye, calcein  
15 (Molecular Probes, Eugene, OR). Polycarbonate filters used in this assay were PVP-free (Neuroprobe Inc.); filter pore sizes used for different cell types were: 5  $\mu$ m for monocytes and THP-1 cells, 3  $\mu$ m for polymorphonuclear leukocytes, and 8  $\mu$ m for guinea pig macrophages.

Fifty thousand calcein labeled cells were resuspended in RPMI  
20 medium containing 2 mg/ml BSA and placed in the upper wells. MDC or other test substances were diluted in RPMI with BSA (e.g., final MDC concentrations of 25, 50, 100, 250 ng/ml) and placed in the lower wells. Following incubation at 37 °C for 2 hours, unmigrated cells remaining above the filter were removed by wiping; the filter was then air-dried. Controls in  
25 these assays were: RPMI with BSA as the negative control, and 50 ng/ml of MCP-1 and 1% zymosan activated serum (ZAS, prepared as described [Denholm and Lewis, *Amer. J. Pathol.*, 126:464-474, (1987)]) were used as positive controls. Migration of cells was quantitated on a fluorescent plate reader (Cytofluor, Millipore Inc. Bedford, MA) and the number of cells  
30 migrated expressed as fluorescent units.

- 54 -

In assays of inhibitory activity, cells in the upper wells of the chambers were suspended in varying concentrations (0.005, 0.05, 0.5, 5.0, and 50 ng/ml) of MDC. The lower wells of the chamber were filled with either medium alone or the chemotactic factors, MCP-1 or zymosan activated serum (ZAS). Inhibition was assessed by comparing the number of cells that migrated to MCP-1 or ZAS, in the absence of MDC, to the number of cells that migrated with increasing concentrations of MDC. Preparation of cells and quantitation of assays was performed exactly as described above for the chemotaxis assays. The number of cells migrated was expressed as fluorescent units.

As indicated in Figure 2, MDC did not induce THP-1-derived mononuclear cell migration, but rather appeared to inhibit mononuclear cell migration, at concentrations between 10 and 100 ng/ml. Other C-C chemokines, such as MCP-1 and RANTES, typically induce maximal monocyte chemotaxis within this concentration range.

As shown in Figure 3, MDC, at concentrations of .001 to 100 ng/ml had no net effect on granulocyte migration. In respect to this lack of effect on granulocyte chemotaxis, MDC is similar to other previously described C-C chemokines.

The response of both macrophage and monocyte THP-1 cells to MDC is shown in Figure 4. Macrophages (closed circles) migrated to MDC in a dose dependent manner, with optimal activity at 50 ng/ml. The decrease in macrophage chemotactic response to MDC at higher concentrations (100 ng/ml) reflects a desensitization of cells which is typical of most chemotactic factors at high concentrations [Falk and Leonard, *Infect. Immunol.*, 32:464-468 (1981)]. Monocytic THP-1 cells (open circles) however, did not migrate to MDC.

The chemotactic activity of MDC for macrophages was further verified in experiments utilizing elicited guinea pig peritoneal macrophages.



- 55 -

MDC induced a dose dependent migration of guinea pig macrophages (Figure 5), at concentrations between 100 and 500 ng/ml. The concentrations necessary to induce the migration of guinea pig macrophages was approximately ten-fold of that for human cells (fig. 4). Similar differences in  
5 concentrations necessary for peak biological activity of human chemokines in other species have been reported for MCP-1 by Yashimura, *J. Immunol.*, 150:5025-5032 (1993).

The results of these experiments suggest that the biological activities of MDC are linked to the differentiation of monocytes to  
10 macrophages. In contrast to MCP-1 [Yoshimura, *J. Immunol.*, 150:5025-5032 (1993)], MDC induces macrophage but not monocyte chemotaxis.

The ability of MDC to attract macrophages indicates that this chemokine might act to induce the focal accumulation of tissue macrophages. The accumulation of tissue macrophages in specific areas is important in the  
15 formation of granulomas, in which lung macrophages act to surround and enclose foreign particulates or relatively nondestructible bacterial pathogens such as *Mycobacterium sp.* [Adams, *Am.J. Pathol.*, 84:164-191 (1976)].

In certain conditions such as arthritis, the accumulation of macrophages is understood to be detrimental and destructive. The ability of  
20 MDC to promote macrophage chemotaxis indicates a therapeutic utility for MDC inhibitors of the invention, to prevent, reduce, or eliminate macrophage accumulation in tissues.

The results of the chemotaxis assays with human mononuclear cells, presented in Figure 2, suggested that MDC might inhibit cell migration.  
25 In the absence of MDC, monocytic THP-1 cells migrate to MCP-1, as shown in Figure 6 (MDC of 0 ng/ml). However, when cells are exposed to MDC, the chemotactic response to MCP-1 (closed circles) is decreased. MDC, at concentrations of 0.005-0.5 ng/ml, inhibited monocyte chemotactic response to MCP-1. Although MDC inhibited the chemotactic response of monocytes  
30 to MCP-1, there was no significant effect of MDC on chemokinesis, or

- 56 -

random migration, as reflected by the numbers of cells migrating to medium alone (open circles, RPMI with BSA), either in the presence of absence of MDC.

5       The inhibitory activity of MDC on monocyte chemotaxis indicates therapeutic utility for MDC in the treatment of several chronic inflammatory conditions (atherosclerosis, arthritis, pulmonary fibrosis) in which monocyte chemotaxis appears to play an important pathogenic role. Enhancing the activity of MDC in such diseases might result in the decreased migration of monocytes into tissues, thereby lessening the severity of disease  
10       symptoms.

#### Example 14

##### MDC *In Vivo* Tumor Growth Inhibition Assay

Tumor growth-inhibition properties of MDC are assayed, *e.g.*, by modifying the protocol described by Laning *et al.*, *J. Immunol.*,  
15       153:4625-4635 (1994) for assaying the tumor growth-inhibitory properties of murine TCA3. An MDC-encoding cDNA is transfected by electroporation into the myeloma-derived cell line J558 (American Type Culture Collection, Rockville, MD). Transfectants are screened for MDC production by standard techniques such as ELISA (enzyme-linked immunoadsorbant assay) using a  
20       monoclonal antibody generated against MDC as detailed in Example 18. A bolus of 10 million cells from an MDC-producing clone is injected subcutaneously into the lower right quadrant of BALB/c mice. For comparison, 10 million non-transfected cells are injected into control mice. The rate and frequency of tumor formation in the two groups is compared to  
25       determine efficacy of MDC in inhibiting tumor growth. The nature of the cellular infiltrate subsequently associated with the tumor cells is identified by histologic means. In addition, recombinant MDC (20 ng) is mixed with non-transfected J558 cells and injected (20 ng/day) into tumors derived from such cells, to assay the effect of MDC administered exogenously to tumor cells.

- 57 -

### Example 15

#### Intraperitoneal Injection Assay

The cells which respond to MDC *in vivo* are determined through injection of 1-1000 ng of purified MDC into the intraperitoneal cavity of mice or other mammals (e.g., rabbits or guinea pigs), as described by Luo *et al.*, *J. Immunol.*, 153:4616-4624 (1994). Following injection, leukocytes are isolated from peripheral blood and from the peritoneal cavity and identified by staining with the Diff Quick kit (Baxter, McGraw, IL). The profile of leukocytes is measured at various times to assess the kinetics of appearance of different cell types. In separate experiments, neutralizing antibodies directed against MDC (Example 18) are injected along with MDC to confirm that the infiltration of leukocytes is due to the activity of MDC.

### Example 16

#### *In vivo* Activity Assay - Subcutaneous Injection

The chemoattractant properties of MDC are assayed *in vivo* by adapting the protocol described by Meurer *et al.*, *J. Exp. Med.*, 178:1913-1921 (1993). Recombinant MDC (10-500 pmol/site) is injected intradermally into a suitable mammal, e.g., dogs or rabbits. At times of 4 to 24 hours, cell infiltration at the site of injection is assessed by histologic methods. The presence of MDC is confirmed by immunocytochemistry using antibodies directed against MDC. The nature of the cellular infiltrate is identified by staining with Baxter's Diff Quick kit.

### Example 17

#### Myelosuppression Activity Assays

The myelosuppressive activity of MDC is assayed by injection of MDC into mice or another mammal (e.g. rabbits, guinea pigs), e.g., as described by Maze *et al.*, *J. Immunol.*, 149:1004-1009 (1992) for the measurement of the myelosuppressive action of MIP-1 $\alpha$ . A single dose of 0.2

- 58 -

to 10 ug of recombinant MDC is intravenously injected into C3H/HeJ mice (Jackson Laboratories, Bar Harbor ME). The myelosuppressive effect of the chemokine is determined by measuring the cycling rates of myeloid progenitor cells in the femoral bone marrow and spleen. The suppression of growth and  
5 division of progenitor cells has clinical implications in the treatment of patients receiving chemotherapy or radiation therapy. The myeloprotective effect of such chemokine treatment has been demonstrated in pre-clinical models by Dunlop *et al.*, *Blood*, 79:2221 (1992).

An *in vitro* assay also is employed to measure the effect of MDC on  
10 myelosuppression, in the same manner as described previously for derivatives of the chemokines interleukin-8 (IL-8) and platelet factor 4 (PF-4). See Daly *et al.*, *J. Biol. Chem.*, 270:23282 (1995). Briefly, low density (less than 1.077 g/cm) normal human bone marrow cells are plated in 0.3% agar culture medium with 10% fetal bovine serum (HyClone, Logan, UT) with 100  
15 units/ml recombinant human GM-CSF (R&D Systems, Minneapolis, MN) plus 50 ng/ml recombinant human Steel factor (Immunex Corp., Seattle, WA) in the absence (control) and presence of MDC for assessment of granulocyte-macrophage precursors. For assessment of granulocyte erythroid myeloid megakaryocyte colony forming units (CFU-GEMM) and erythroid  
20 burst forming units (BFU-E), cells are grown in 0.9% methylcellulose culture medium in the presence of recombinant human erythropoietin (1-2 units/ml) in combination with 50 ng/ml Steel factor. Plates are scored for colonies after incubation at 37 °C in lowered (5%) O<sub>2</sub> for 14 days. The combination of GM-CSF and Steel factor or erythropoietin and Steel factor allow detection of  
25 large colonies (usually >1000 cells/colony) which come from early, more immature subsets of granulocyte myeloid colony forming units (CFU-GM), CFU-GEMM, and BFU-E.

- 59 -

**Example 18**

**Antibodies to Human MDC**

**A. Monoclonal antibodies**

Recombinant MDC, produced by cleavage of a GST-MDC  
5 fusion protein as described in Example 6, was used to immunize a mouse for  
generation of monoclonal antibodies. In addition, a separate mouse was  
immunized with a chemically synthesized peptide corresponding to the N-  
terminus of the mature form of MDC (residues 1 to 12 of SEQ ID NO. 2).  
The peptide was synthesized on an Applied Biosystem Model 473A Peptide  
10 Synthesizer (Foster City, CA), and conjugated to Keyhole Limpet  
Hemocyanine (Pierce), according to the manufacturer's recommendations.  
For the initial injection, approximately 10  $\mu$ g of MDC protein or conjugated  
peptide was emulsified with Freund's Complete Adjuvant and injected  
subcutaneously. At intervals of two to three weeks, additional aliquots of  
15 MDC protein were emulsified with Freund's Incomplete Adjuvant and injected  
subcutaneously. Prior to the final perfusion boost, a sample of serum was  
taken from the immunized mice. These sera were assayed by western blot to  
confirm their reactivity with MDC protein. For a perfusion boost, the mouse  
was injected with MDC in PBS, and four days later the mouse was sacrificed  
20 and its spleen removed. The spleen was placed in 10 ml serum-free RPMI  
1640, and a single cell suspension was formed by grinding the spleen between  
the frosted ends of two glass microscope slides submerged in serum-free  
RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate,  
100 units/ml penicillin, and 100  $\mu$ g/ml streptomycin (RPMI) (Gibco, Canada).  
25 The cell suspension was filtered through sterile 70-mesh Nitex cell strainer  
(Becton Dickinson, Parsippany, New Jersey), and was washed twice by  
centrifuging at 200 g for 5 minutes and resuspending the pellet in 10 ml  
serum-free RPMI. Thymocytes taken from three naive Balb/c mice were  
prepared in a similar manner and used as a Feeder Layer. NS-1 myeloma  
30 cells, kept in log phase in RPMI with 10% fetal bovine serum (FBS) (Hyclone

- 60 -

Laboratories, Inc., Logan, Utah) for three days prior to fusion, were centrifuged at 200 g for 5 minutes, and the pellet was washed twice as described in the foregoing paragraph.

Spleen cells ( $2 \times 10^8$ ) were combined with  $4 \times 10^7$  NS-1 cells and centrifuged, and the supernatant was aspirated. The cell pellet was dislodged by tapping the tube, and 2 ml of 37°C PEG 1500 (50% in 75mM Hepes, pH 8.0) (Boehringer Mannheim) was added with stirring over the course of 1 minute, followed by the addition of 14 ml of serum-free RPMI over 7 minutes. An additional 16 ml RPMI was added and the cells were centrifuged at 200 g for 10 minutes. After discarding the supernatant, the pellet was resuspended in 200 ml RPMI containing 15% FBS, 100  $\mu$ M sodium hypoxanthine, 0.4  $\mu$ M aminopterin, 16  $\mu$ M thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and  $1.5 \times 10^6$  thymocytes/ml and plated into 10 Corning flat-bottom 96-well tissue culture plates (Corning, Corning New York).

On days 2, 4, and 6, after the fusion, 100  $\mu$ l of medium was removed from the wells of the fusion plates and replaced with fresh medium. On day 8, the fusion was screened by ELISA, testing for the presence of mouse IgG binding to MDC as follows. Immulon 4 plates (Dynatech, Cambridge, MA) were coated for 2 hours at 37°C with 100 ng/well of MDC diluted in 25mM Tris, pH 7.5. The coating solution was aspirated and 200  $\mu$ l/well of blocking solution [0.5% fish skin gelatin (Sigma) diluted in CMF-PBS] was added and incubated for 30 min. at 37°C. The blocking solution was aspirated and 50  $\mu$ l culture supernatant was added. After incubation at 37°C for 30 minutes, and washing three times with PBS containing 0.05% Tween 20 (PBST), 50  $\mu$ l of horseradish peroxidase conjugated goat anti-mouse IgG(fc) (Jackson ImmunoResearch, West Grove, Pennsylvania) diluted 1:7000 in PBST was added. Plates were incubated as above, washed four times with PBST, and 100  $\mu$ L substrate, consisting of 1 mg/ml *o*-phenylene diamine (Sigma) and 0.1  $\mu$ l/ml 30%  $H_2O_2$  in 100 mM Citrate, pH 4.5, was added.

- 61 -

The color reaction was stopped after 5 minutes with the addition of 50  $\mu$ l of 15%  $H_2SO_4$ .  $A_{490}$  was read on a plate reader (Dynatech).

Selected fusion wells were cloned twice by dilution into 96-well plates and visually scored for the number of colonies/well after 5 days. The monoclonal antibodies produced by hybridomas were isotyped using the

5 Isostrip system (Boehringer Mannheim, Indianapolis, IN).

Anti-MDC antibodies were characterized further by western blotting against recombinant MDC produced as described above in *E. coli* or mammalian CHO cells. To prepare the blot, approximately 3  $\mu$ l of

10 sedimented cells (transformed *E. coli* producing MDC; transfected CHO cells producing MDC; untransformed *E. coli* (control); and untransfected CHO cells (control)) were dissolved in standard sample preparation buffer containing SDS (sodium dodecyl sulfate) and DTT (dithiothreitol) (Sambrook

15 *et al.*). After boiling, the lysates were fractionated via denaturing SDS-PAGE (18% acrylamide, Tris Glycine gel, NOVEX) and electroblotted to PVDF membranes (Millipore, Bedford, MA). MDC monoclonal antibodies were diluted to 0.7  $\mu$ g/ml in PBS for use in the western blotting, following standard techniques (Sambrook *et al.*). As an additional control, the monoclonal antibodies were further tested for cross-reactivity on western blots of whole

20 tissue lysates of human skin, tonsil, and thymus.

One anti-MDC monoclonal antibody, designated monoclonal antibody 191D, reacted strongly with recombinant MDC produced by both bacteria and mammalian cells. Further, this antibody displayed very little background reactivity against bacteria, the CHO mammalian cell line, or the

25 whole human tissues tested. In addition, this antibody showed the ability to immunoprecipitate recombinant CHO-derived MDC, following standard immunoprecipitation protocols (Sambrook *et al.*).

The hybridoma cell line which produces monoclonal antibody 191D (designated hybridoma 191D) has been deposited with the American

30 Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville MD

- 62 -

20852 (USA) pursuant to the provisions of the Budapest Treaty (ATCC  
Deposit date: June 04, 1996; ATCC Accession No. HB-12122). Availability  
of the deposited material is not to be construed as a license to practice the  
invention in contravention of the rights granted under the authority of any  
5 government in accordance with its patent laws.

B. Polyclonal antibodies.

Polyclonal antibodies against MDC were raised in rabbits  
following standard protocols (Sambrook *et al.*). Recombinant MDC produced  
as a GST fusion protein as described above was diluted in PBS, emulsified  
10 with Freund's Complete Adjuvant, and injected subcutaneously into rabbits.  
At intervals of three and six weeks, additional MDC diluted in PBS was  
emulsified with Freund's Incomplete Adjuvant and injected subcutaneously  
into the same rabbits. Ten days after the third immunization, serum was  
withdrawn from the rabbits and diluted ten-fold in Tris-buffered saline with  
15 0.5% Tween 20 (TBS-T, Sambrook *et al.*) for characterization via western  
blotting against recombinant MDC as described above.

Example 19

Calcium flux assay

Changes in intracellular calcium concentrations, indicative of  
20 cellular activation by chemokines, were monitored in several cell lines by an  
art-recognized calcium flux assay. Cells were incubated in 1 ml complete  
media containing 1  $\mu$ M Fura-2/AM (Molecular Probes, Eugene, OR) for 30  
minutes at room temperature, washed once, and resuspended in D-PBS at  
~ 10<sup>6</sup> cells/ml.

25 Two ml of suspended cells were placed in a continuously stirred  
cuvette at 37°C in a fluorimeter (AMINCO-Bowman Series 2, Rochester,  
NY). The concentration of intracellular calcium was indicated by  
fluorescence, which was monitored at 510 nm emission wavelength while



- 63 -

switching between excitation wavelengths of 340 nm and 380 nm every 0.5 seconds. The ratio of the emissions from the 340 nm relative to the 380 nm excitation wavelengths corresponds to the level of intracellular calcium.

Cell lines measured by this assay included the following: the  
5 human embryonic kidney cell line HEK-293 stably transfected with the putative chemokine receptor gene V28 [Raport et al., *Gene*, 163:295-299 (1995)]; HEK-293 cells stably transfected with the chemokine receptor gene CCR5 [Samson et al., *Biochemistry*, 35:3362-3367 (1996); see also co-owned, co-pending U.S. Patent Application Serial No. 08/575,967, filed December  
10 20, 1995, incorporated herein by reference, disclosing chemokine receptor materials and methods, including CCR5 (identified therein as "88C")], the human monocytic cell line THP-1, the human lung epithelial cell line A-549; and the human fibroblast cell line IMR-90. None of these cell lines fluxed calcium in response to the recombinant MDC protein. As positive controls,  
15 the HEK-293 transfectants responded strongly to thrombin, indicating that the assay was valid. In addition, the THP-1 cells responded strongly to the commercially available chemokines MCP-1 and MCP-3 (Peprotech, Rocky Hill, NJ) at a final concentration of 25 ng/ml. No additional stimuli were tested on the A-549 or IMR-90 cell lines.

20

### Example 20

#### Inhibition of HIV proliferation

Several CC chemokines have been implicated in suppressing the proliferation of Human Immunodeficiency Virus (HIV), the causative agent of human Acquired Immune Deficiency Syndrome (AIDS). See Cocchi et al.,  
25 *Science*, 270:1811 (1995). The HIV antiproliferative activity of MDC is measured by means such as those described by Cocchi et al., in which a CD4<sup>+</sup> T cell line is acutely infected with an HIV strain and cultured in the presence of various concentrations of MDC. After three days, a fresh dilution of MDC in the culture medium is added to the cells. At 5 to 7 days following

- 64 -

infection, the level of HIV is measured by testing the culture supernatants for the presence of HIV p24 antigen by a commercial ELISA test (Coulter, Miami, FL).

Antibodies against MDC are tested for their ability to neutralize the suppressive activity produced by human lymphocytes (Cocchi, supra). In addition, the efficacy of chemically synthesized MDC analogs (Ex. 11) or analogs produced by recombinant methods is also tested in assays of HIV inhibition.

### Example 21

#### Effects of MDC on Fibroblast Proliferation

In addition to their ability to attract and activate leukocytes, some chemokines, such as IL-8, have been shown to be capable of affecting the proliferation of non-leukocytic cells [see Tuschil, *J. Invest. Dermatol.*, 99:294-298 (1992)]. Fibroblasts throughout the body are important to the structural integrity of most tissues. The proliferation of fibroblasts is essential to wound healing and response to injury but can be deleterious as well, as in the case of chronic inflammatory diseases, such as pulmonary fibrosis [Phan, in: Immunology of Inflammation, Elsevier (1983), pp. 121-162].

*In vitro* cell proliferation assays were utilized to assess the effects of MDC on the proliferation of fibroblasts. Human fibroblasts (CRL-1635) were obtained from ATCC and maintained in culture in DMEM with 10% FBS and 1% antibiotics. Proliferation assays were performed and quantitated as previously described in the art by Denholm and Phan, *Amer. J. Pathol.*, 134:355-363 (1989). Briefly, on day 1,  $2.5 \times 10^3$  cells/well were plated into 96 well plates in DMEM with 10% FBS. Day 2: twenty-four hours after plating, medium on cells was changed to serum-free DMEM. Day 3: medium was removed from cells and replaced with MDC diluted in DMEM containing 0.4% FBS. Day 5: one microCurie of  $^3\text{H}$ -thymidine was added per well and incubation continued for an additional 5 hours. Cells were

- 65 -

harvested onto glass fiber filters. Cell proliferation was expressed as cpm of <sup>3</sup>H-thymidine incorporated into fibroblasts. Controls for this assay included the basal medium for this assay, DMEM with 0.4% FBS as the negative control, and DMEM with 10% FBS as the positive control.

5                   As shown in Figure 7, MDC treatment decreased the proliferation of fibroblasts in a dose dependent manner. Similar inhibition of fibroblast proliferation was observed with both MDC purified from CHO cells (closed circles) and chemically synthesized MDC (open circles). The fibroblast-antiproliferative effect of MDC indicates a therapeutic utility for  
10 MDC in the treatment of diseases such as pulmonary fibrosis and tumors, in which enhanced or uncontrolled cell proliferation is a major feature.

### Example 22

#### Cell Proliferation Assays

The effects of MDC upon the proliferation of epithelial cells,  
15 T cells, fibroblasts, endothelial cells, macrophages, and tumor cells are assayed by methods known in the art, such as those described in Denholm *et al.*, *Amer. J. Pathol.*, 134:355-363 (1989), and "In Vitro Assays of Lymphocyte Functions," in: *Current Protocols Immunology*, Sections 3-4, Wiley and Sons (1992), for the assay of growth factor activities. In these  
20 methods, enhancement or inhibition of cell growth and the release of growth factors are measured.

MDC effects on the proliferation of epithelial cells and endothelial cells are assayed using the same procedures as those described above for fibroblasts (Example 21).

25                   The effects on the proliferation of T cells are determined using peripheral blood lymphocytes. Mononuclear cells are isolated from peripheral blood as described in Denholm *et al.*, *Amer. J. Pathol.*, 135:571-580 (1989); cells are resuspended in RPMI with 10% FBS and incubated overnight in plastic tissue culture flasks. Lymphocytes remain in suspension in these

- 66 -

cultures and are obtained by centrifugation of culture medium. One hundred thousand lymphocytes are plated into each well of a 96 well plate and incubated for three days in medium (RPMI plus 10% FBS) containing 1  $\mu$ g/ml PHA with or without 50, 125, 250 or 500 ng/ml of MDC. One microCurie of  $^3$ H-thymidine is added during the last 18 hours of incubation. Cells are harvested and proliferations expressed as described for fibroblasts in Example 21.

The effects of MDC on macrophage proliferation are determined using elicited guinea pig peritoneal macrophages, obtained as described above in Example 13. Macrophages are plated into 96 well plates at a density of one hundred thousand cells per well in RPMI with 10% FBS, and incubated 2 hours to allow cells to adhere. Medium is then removed and replaced with fresh medium with or without 50, 125, 250 or 500 ng/ml of MDC. Cells with MDC are incubated three days, and proliferation is determined as described above for lymphocytes.

Chemokine-mediated control of the proliferation of these cell types has therapeutic implications in enhancing tissue repair following injury, and in limiting the proliferation of these cells in chronic inflammatory reactions such as psoriasis, fibrosis, and atherosclerosis, and in neoplastic conditions.

### Example 23

#### In Vivo Fibroblast Proliferation Assay

The anti-proliferative effects of MDC upon fibroblasts are determined *in vivo* by the methods known in the art, such as those reported by Phan and Fantone, *Amer. J. Pathol.*, 50:587-591 (1984), which utilize a rat model of pulmonary fibrosis in which the disease is induced by bleomycin. This model is well-characterized and allows for the assessment of fibroblast proliferation and collagen synthesis during all stages of this disease.

- 67 -

Briefly, rats are divided into four treatment groups: 1) controls, given intratracheal injections of normal saline; 2) saline-injected rats which also receive a daily intraperitoneal injection of 500 ng of MDC in saline; 3) bleomycin-treated, given an intratracheal injection of 1.5 mg/kg  
5 bleomycin (Calbiochem, Palo Alto, CA); and 4) bleomycin-treated rats which also are given a daily intraperitoneal injection of 500 ng of MDC.

Three rats per group are sacrificed at 4, 7, 14, 21, and 28 days after the initial intratracheal injections. Lungs are removed and samples of each lobe taken for histological examination and assays of collagen content.

10

#### Example 24

##### MDC Modulator Assays

Modulators of MDC activity may be useful for the treatment of diseases or symptoms of diseases wherein MDC plays a role. Such modulators may be either agonists or antagonists of MDC binding. The  
15 following receptor binding assays provide procedures for identifying such MDC modulators.

MDC is labeled with a detectable label such as  $^{125}\text{I}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$ , biotin, or Europium. A preparation of cell membranes containing MDC receptors is prepared from natural cells that respond to MDC, such as human  
20 macrophages, phorbol ester-stimulated THP-1 cells, human fibroblasts, human fibroblast cell lines, or guinea pig macrophages. (Alternatively, a recombinant receptor preparation is made from cells transfected with an MDC receptor cDNA, when such an MDC receptor cDNA is identified and cloned.)

The membrane preparation is exposed to  $^{125}\text{I}$ -labeled MDC, for example, and  
25 incubated under suitable conditions (e.g., ten minutes at  $37^\circ\text{C}$ ). The membranes, with any bound  $^{125}\text{I}$ -MDC, are then collected on a filter by vacuum filtration and washed to remove unbound  $^{125}\text{I}$ -MDC. The radioactivity

- 68 -

associated with the bound MDC is then quantitated by subjecting the filters to liquid scintillation spectrophotometry.

The specificity of MDC binding may be confirmed by repeating the foregoing assay in the presence of increasing quantities of unlabelled MDC, and measuring the level of competition for binding to the receptor. These binding assays also can be employed to identify modulators of MDC receptor binding.

The foregoing receptor binding assay also may be performed with the following modification: in addition to labeled MDC, a potential MDC modulator is exposed to the membrane preparation. In this assay variation, an increased level (quantity) of membrane-associated label indicates the potential modulator is an activator of MDC binding; a decreased level (quantity) of membrane-associated label indicates the potential modulator is an inhibitor of MDC receptor binding. This assay can be utilized to identify specific activators and inhibitors of MDC binding from large libraries of chemical compounds or natural products. Rapid screening of multiple modulator candidate compounds simultaneously is specifically contemplated.

The biological functions of MDC, elucidated as described above, suggest several clinical applications.

Chemokines in general attract and activate monocytes and macrophages (Baggiolini *et al.*, *supra*), and MDC in particular attracts macrophages and inhibits monocyte chemotaxis. Thus, MDC expression in a pathogenic inflammatory setting may exacerbate disease states by recruiting additional macrophages or other leukocytes to the disease site, by activating the leukocytes that are already there, or by inducing leukocytes to remain at the site. Thus, inhibiting the chemoattractant activity of MDC may be expected to alleviate deleterious inflammatory processes. Significantly, the potential benefits of such an approach have been directly demonstrated in experiments involving IL-8, a C-X-C chemokine that attracts and activates

- 69 -

neutrophils. Antibodies directed against IL-8 have a profound ability to inhibit inflammatory disease mediated by neutrophils [Harada *et al.*, *J. Leukoc. Biol.*, 56:559 (1994)]. Inhibition of MDC is expected to have a similar effect in diseases in which macrophages are presumed to play a role,  
5 *e.g.*, Crohn's disease, rheumatoid arthritis, or atherosclerosis.

Alternatively, augmenting the effect of MDC may have a beneficial role in such diseases, as chemokines have also been shown to have a positive effect in wound healing and angiogenesis. Thus, exogenous MDC or MDC agonists may be beneficial in promoting recovery from such diseases.

10 In addition, the myelosuppressive effect demonstrated for the C-C chemokine MIP-1 $\alpha$  (Maze *et al.*, *supra*) suggests that MDC may have a similar activity. Such activity, provided by MDC or MDC agonists, may yield substantial benefits for patients receiving chemotherapy or radiation therapy, reducing the deleterious effects of the therapy on the patient's  
15 myeloid progenitor cells.

MDC or MDC agonists may also prove to be clinically important in the treatment of tumors, as suggested by the ability of the C-C chemokine TCA3 to inhibit tumor formation in mice (see Laning *et al.*, *supra*). MDC may act directly or indirectly to inhibit tumor formation, *e.g.*,  
20 by attracting and activating various non-specific effector cells to the tumor site or by stimulating a specific anti-tumor immunity. The fibroblast-antiproliferative effect of MDC indicates a therapeutic utility for MDC in the treatment of diseases such as pulmonary fibrosis and tumors, in which enhanced or uncontrolled cell proliferation is a major feature.

25 While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

- 70 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Godiska, Ronald  
Gray, Patrick W.
  - (ii) TITLE OF INVENTION: MACROPHAGE DERIVED CHEMOKINE AND CHEMOKINE ANALOGS
  - (iii) NUMBER OF SEQUENCES: 32
  - (iv) CORRESPONDENCE ADDRESS:
    - (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
    - (B) STREET: 6300 Sears Tower, 233 South Wacker Drive
    - (C) CITY: Chicago
    - (D) STATE: Illinois
    - (E) COUNTRY: United States of America
    - (F) ZIP: 60606-6402
  - (v) COMPUTER READABLE FORM:
    - (A) MEDIUM TYPE: Floppy disk
    - (B) COMPUTER: IBM PC compatible
    - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
    - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER:
    - (B) FILING DATE:
    - (C) CLASSIFICATION:
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: 08/558,658
    - (B) FILING DATE: 16-NOV-1995
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: 08/479,620
    - (B) FILING DATE: 07-JUN-1995
  - (viii) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: Gass, David A.
    - (B) REGISTRATION NUMBER: 38,153
    - (C) REFERENCE/DOCKET NUMBER: 27866/33318
  - (ix) TELECOMMUNICATION INFORMATION:
    - (A) TELEPHONE: 312/474-6300
    - (B) TELEFAX: 312/474-0448
    - (C) TELEX: 25-3856
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 2923 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (ix) FEATURE:
    - (A) NAME/KEY: CDS
    - (B) LOCATION: 20..298



- 71 -

## (ix) FEATURE:

(A) NAME/KEY: mat\_peptide

(B) LOCATION: 92..298

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC GTC TGC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	
GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG	408
CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCAC TGCC	468
ATCTCCCCCC TGACCCCTCT AACCCATCCT CTGCCCTCCCT CCCTGCAGTC AGAGGGTCTT	528
GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA	588
GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG	648
CCTGCCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCAA ACCCATACTA	708
CACATCCCAC TTCTGGGTCT TTGCCTGGGA TGTGCTGAC ACTCAGAAAG TCCCACCACC	768
TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC	828
CATTTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCTC TTAATAACCC TAGTCACAGT	888
CTCCGCAGAT TCTTGGGATT TGGGGGTTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG	948
GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCCC	1008
TGGCTCAGAA TCAGAGCCCCA GAAAGTGGCT GCAGACAAA TCAATAAAAC TAATGTCCCT	1068
CCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT	1128
GGGCCAGCTG GGTCATGTG AAGCCCCAAA TTTGCCCAGA TTCACCTTTC TTCCCCCACT	1188
CCCTTTTTTT TTTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTCACCCA CGCTGGAGTG	1248

- 72 -

CAATGGTGTG GTCTTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAGTG ATTCTCTTGC	1308
CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCCTGCTAC CACGCCCAGC TAATTTTTGT	1368
ATTTTITAGTA GAGACGAGGC TTCACCATGT TGGCCAGGCT GGTCTCGAAC TCCTGTCCTC	1428
AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC	1488
CTGGCCTCTT CCCTCTCCCC ACTGCCCCCC CCAACTTTTT TTTTTTTTTT ATGGCAGGGT	1548
CTCACTCTGT CGCCAGGCT GGAGTGCAGT GGCCTGATCT CGGCTCACTA CAACCTCGAC	1608
CTCCTGGGTT CAAGTGATTC TCCCACCCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGTG	1668
TGCCACTACG GCTGGCTAAT TTTTGTATTT TTAGTAGAGA CAGGTTTCAC CATATTGGCC	1728
AGGCTGGTCT TGAATCCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGCTG	1788
AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTTT TTTTCCTAAT AGGAGACTCC	1848
TGTACCTTTC TTCGTTTAC CTATGTGTCG TGTCTGCTTA CATTCCTTC TCCCCTCAGG	1908
CTTTTTTTGG GTGGTCTCC AACCTCCAAT ACCCAGGCCT GGCCTCTTCA GAGTACCCCC	1968
CATTCCACTT TCCCTGCCTC CTTCTTAAA TAGCTGACAA TCAAATTCAT GCTATGGTGT	2028
GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATTT GAAAACAGAG	2088
TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTTT AGGAACTGTG AGAGGGGGAC	2148
AAGGTGAAGC TTTCTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC	2208
TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG	2268
ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCTTTC	2328
TGGCTGATTT TTGTAGAGAC GGGGTTTTGC CATGTTACCC AGGCTGGTCT CAAACTCCTG	2388
GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC	2448
TGCGCCTGGC TTCCTCTTCC TCTTGAGAAA TATTCTTTTC ATACAGCAAG TATGGGACAG	2508
CAGTGTCCCA GTTAAAGGAC ATAAATGTTA CAAGTGTCTG GTCCTTTCTG AGGGAGGCTG	2568
GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTT ACTCCCTGAA	2628
CCCAGCCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT	2688
TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTCATCCA GGGCCTGTGT	2748
CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC	2808
TGCCCATGAA CGGGGCCCTC AAGCGTCCTG GGATCTCCTT CTCCCTCCTG TCCTGTCCTT	2868
GCCCCTCAGG ACTGCTGGAA AATAAATCCT TTAAATAGT AAAAAAAAAA AAAAA	2923

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 93 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

- 73 -

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val Leu Val Leu Leu Ala
-24          -20          -15          -10
Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
          -5          1          5
Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
    10          15          20
Val Val Lys His Phe Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
    25          30          35          40
Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
          45          50          55
Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
          60          65

```

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GACACTATAG AATAGGGC

18

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 17 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTAAAACGAC GGCCAGT

17

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AATTAACCTT CACTAAAGGG

20

- 74 -

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTAATACGAC TCACTATAGG GC

22

## (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TCTATCTAGA GGCCCCTACG GCGCCAACAT GGAAG

35

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 33 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CACCGGATCC TCATTGGCTC AGCTTATTGA GAA

33

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AATGGATCCA CAGCACGGAG GTGACCAAG

29

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 31 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- 75 -

- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
- AGTCAAGCTT AGGGCACTCT GGGATCGGCA C 31
- (2) INFORMATION FOR SEQ ID NO:11:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 45 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
- TATCGGATCC TGGTCCGCG TGGCCCCTAC GGCGCCAACA TGGAA 45
- (2) INFORMATION FOR SEQ ID NO:12:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
- GAAATCCAGC AAGTATATAG CA 22
- (2) INFORMATION FOR SEQ ID NO:13:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
- ATTGCCATGG CCGGCCCCCTA CGGCGCCAAC ATGGAA 36
- (2) INFORMATION FOR SEQ ID NO:14:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
- GACCAAGCTT GAGACATACA GGACAGAGCA 30

- 76 -

## (2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TGGATCTAGA AGTTGGCACA GGCTTCTGG

29

## (2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CGAAATTAAT ACGACTCACT

20

## (2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 67 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGGATCTAGA TCAATTCAAG TCCTCCTCGC TGATCAGCTT CTGCTCTTGG CTCAGCTTAT  
TGAGAAT

60

67

## (2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 99 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc\_feature

(D) OTHER INFORMATION: "Hu MCP-3"

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..76

- 77 -

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

Met Lys Ala Ser Ala Ala Leu Leu Cys Leu Leu Leu Thr Ala Ala Ala
      -20                      -15                      -10

Phe Ser Pro Gln Gly Leu Ala Gln Pro Val Gly Ile Asn Thr Ser Thr
      -5                      1                      5

Thr Cys Cys Tyr Arg Phe Ile Asn Lys Lys Ile Pro Lys Gln Arg Leu
10                      15                      20                      25

Glu Ser Tyr Arg Arg Thr Thr Ser Ser His Cys Pro Arg Glu Ala Val
      30                      35                      40

Ile Phe Lys Thr Lys Leu Asp Lys Glu Ile Cys Ala Asp Pro Thr Gln
      45                      50                      55

Lys Trp Val Gln Asp Phe Met Lys His Leu Asp Lys Lys Thr Gln Thr
      60                      65                      70

Pro Lys Leu
      75

```

## (2) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 99 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (D) OTHER INFORMATION: "Hu MCP-1"

## (ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..76

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

Met Lys Val Ser Ala Ala Leu Leu Cys Leu Leu Leu Ile Ala Ala Thr
      -20                      -15                      -10

Phe Ile Pro Gln Gly Leu Ala Gln Pro Asp Ala Ile Asn Ala Pro Val
      -5                      1                      5

Thr Cys Cys Tyr Asn Phe Thr Asn Arg Lys Ile Ser Val Gln Arg Leu
10                      15                      20                      25

Ala Ser Tyr Arg Arg Ile Thr Ser Ser Lys Cys Pro Lys Glu Ala Val
      30                      35                      40

Ile Phe Lys Thr Ile Val Ala Lys Glu Ile Cys Ala Asp Pro Lys Gln
      45                      50                      55

Lys Trp Val Gln Asp Ser Met Asp His Leu Asp Lys Gln Thr Gln Thr
      60                      65                      70

```

- 78 -

Pro Lys Thr  
75

## (2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 76 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:  
 (A) NAME/KEY: misc\_feature  
 (D) OTHER INFORMATION: "Hu MCP-2"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
- |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Pro | Asp | Ser | Val | Ser | Ile | Pro | Ile | Thr | Cys | Cys | Phe | Asn | Val | Ile |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Asn | Arg | Lys | Ile | Pro | Ile | Gln | Arg | Leu | Glu | Ser | Tyr | Thr | Arg | Ile | Thr |
|     |     | 20  |     |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Asn | Ile | Gln | Cys | Pro | Lys | Glu | Ala | Val | Ile | Phe | Lys | Thr | Lys | Arg | Gly |
|     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |     |
| Lys | Glu | Val | Cys | Ala | Asp | Pro | Lys | Glu | Arg | Trp | Val | Arg | Asp | Ser | Met |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Lys | His | Leu | Asp | Gln | Ile | Phe | Gln | Asn | Leu | Lys | Pro |     |     |     |     |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     |     |

## (2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 91 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:  
 (A) NAME/KEY: misc\_feature  
 (D) OTHER INFORMATION: "RANTES"
- (ix) FEATURE:  
 (A) NAME/KEY: Protein  
 (B) LOCATION: 1..68
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
- |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Lys | Val | Ser | Ala | Ala | Ala | Leu | Ala | Val | Ile | Leu | Ile | Ala | Thr | Ala |
|     |     |     |     | -20 |     |     |     | -15 |     |     |     |     | -10 |     |     |
| Leu | Cys | Ala | Pro | Ala | Ser | Ala | Ser | Pro | Tyr | Ser | Ser | Asp | Thr | Thr | Pro |
|     | -5  |     |     |     |     | 1   |     |     |     |     | 5   |     |     |     |     |



- 79 -

Cys Cys Phe Ala Tyr Ile Ala Arg Pro Leu Pro Arg Ala His Ile Lys  
 10 15 20 25  
 Glu Tyr Phe Tyr Thr Ser Gly Lys Cys Ser Asn Pro Ala Val Val Phe  
 30 35 40  
 Val Thr Arg Lys Asn Arg Gln Val Cys Ala Asn Pro Glu Lys Lys Trp  
 45 50 55  
 Val Arg Glu Tyr Ile Asn Ser Leu Glu Met Ser  
 60 65

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 91 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (D) OTHER INFORMATION: "MIP-1B"

## (ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..68

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Met Lys Leu Cys Val Thr Val Leu Ser Leu Leu Met Leu Val Ala Ala  
 -20 -15 -10  
 Phe Cys Ser Pro Ala Leu Ser Ala Pro Met Gly Ser Asp Pro Pro Thr  
 -5 1 5  
 Ala Cys Cys Phe Ser Tyr Thr Arg Glu Ala Ser Ser Asn Phe Val Val  
 10 15 20 25  
 Asp Tyr Tyr Glu Thr Ser Ser Leu Cys Ser Gln Pro Ala Val Val Phe  
 30 35 40  
 Gln Thr Lys Arg Ser Lys Gln Val Cys Ala Asp Pro Ser Glu Ser Trp  
 45 50 55  
 Val Gln Glu Tyr Val Tyr Asp Leu Glu Leu Asn  
 60 65

## (2) INFORMATION FOR SEQ ID NO:23:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 92 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature

- 80 -

(D) OTHER INFORMATION: "MIP-1 $\alpha$ "

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..70

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```

Met Gln Val Ser Thr Ala Ala Leu Ala Val Leu Leu Cys Thr Met Ala
   -20                               -15                   -10
Leu Cys Asn Gln Phe Ser Ala Ser Leu Ala Ala Asp Thr Pro Thr Ala
   -5                               1                     5                   10
Cys Cys Phe Ser Tyr Thr Ser Arg Gln Ile Pro Gln Asn Phe Ile Ala
                   15                               20                   25
Asp Tyr Phe Glu Thr Ser Ser Gln Cys Ser Lys Pro Gly Val Ile Phe
                   30                               35                   40
Leu Thr Lys Arg Ser Arg Gln Val Cys Ala Asp Pro Ser Glu Glu Trp
                   45                               50                   55
Val Gln Lys Tyr Val Ser Asp Leu Glu Leu Ser Ala
                   60                               65                   70

```

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 96 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: misc\_feature

(D) OTHER INFORMATION: "I-309"

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..73

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```

Met Gln Ile Ile Thr Thr Ala Leu Val Cys Leu Leu Leu Ala Gly Met
   -20                               -15                   -10
Trp Pro Glu Asp Val Asp Ser Lys Ser Met Gln Val Pro Phe Ser Arg
   -5                               1                     5
Cys Cys Phe Ser Phe Ala Glu Gln Glu Ile Pro Leu Arg Ala Ile Leu
  10                               15                   20                   25
Cys Tyr Arg Asn Thr Ser Ser Ile Cys Ser Asn Glu Gly Leu Ile Phe
                   30                               35                   40
Lys Leu Lys Arg Gly Lys Glu Ala Cys Ala Leu Asp Thr Val Gly Trp
                   45                               50                   55

```

- 81 -

Val Gln Arg His Arg Lys Met Leu Arg His Cys Pro Ser Lys Arg Lys  
60 65 70

## (2) INFORMATION FOR SEQ ID NO:25:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..69

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature

## (D) OTHER INFORMATION:

/note="The amino acid at position 24 is selected from the group consisting of arginine, glycine, alanine, valine, leucine, isoleucine, proline, serine, threonine, phenylalanine, tyrosine, tryptophan, aspartate, glutamate, asparagine, glutamine, cysteine, and methionine."

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature

## (D) OTHER INFORMATION:

/note="The amino acid at position 27 is independently selected from the group consisting of lysine, glycine, alanine, valine, leucine, isoleucine, proline, serine, threonine, phenylalanine, tyrosine, tryptophan, aspartate, glutamate, asparagine, glutamine, cysteine, and methionine."

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature

## (D) OTHER INFORMATION:

/note="The amino acid at position 30 is independently selected from the group consisting of tyrosine, serine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, and cysteine."

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature

## (D) OTHER INFORMATION:

/note="The amino acid at position 50 is independently selected from the group consisting of glutamic acid, lysine, arginine, histidine, glycine, and alanine."

## (ix) FEATURE:

- (A) NAME/KEY: misc\_feature

## (D) OTHER INFORMATION:

/note="The amino acid at position 59 is independently selected from the group consisting of tryptophan, serine, lysine, arginine, histidine, aspartate,

- 82 -

glutamate, asparagine, glutamine, and cysteine."

## (ix) FEATURE:

(A) NAME/KEY: misc\_feature

## (D) OTHER INFORMATION:

/note="The amino acid at position 60 is independently  
selected from the group consisting of valine, serine,  
lysine, arginine, histidine, aspartate, glutamate,  
asparagine, glutamine, and cysteine."

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```

Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val Leu Val Leu Leu Ala
  -20                               -15                       -10

Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
   -5                               1                       5

Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Xaa
  10                               15                       20

Val Val Xaa His Phe Xaa Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
  25                               30                       35                       40

Val Val Leu Leu Thr Phe Arg Asp Lys Xaa Ile Cys Ala Asp Pro Arg
   45                               50                       55

Val Pro Xaa Xaa Lys Met Ile Leu Asn Lys Leu Ser Gln
   60                               65

```

## (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TATTGGATCC GTTCTAGCTC CCTGTTCTCC

30

## (2) INFORMATION FOR SEQ ID NO:27:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CCAAGAATTC CTGCAGCCAC TTTCTGGGCT C

31

## (2) INFORMATION FOR SEQ ID NO:28:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs

- 83 -

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GCGACTCTCT ACTGTTTCTC

20

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CACAGGAAAC AGCTATGACC

20

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 70 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Leu	Gly	Pro	Tyr	Gly	Ala	Asn	Met	Glu	Asp	Ser	Val	Cys	Cys	Arg	Asp
1				5					10					15	
Tyr	Val	Arg	Tyr	Arg	Leu	Pro	Leu	Arg	Val	Val	Lys	His	Phe	Tyr	Trp
		20					25					30			
Thr	Ser	Asp	Ser	Cys	Pro	Arg	Pro	Gly	Val	Val	Leu	Leu	Thr	Phe	Arg
		35				40					45				
Asp	Lys	Glu	Ile	Cys	Ala	Asp	Pro	Arg	Val	Pro	Trp	Val	Lys	Met	Ile
	50					55				60					
Leu	Asn	Lys	Leu	Ser	Gln										
65					70										

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

- 84 -

Gly Pro Tyr Gly Ala Asn Met Glu Asp Ser Val Cys Cys Arg Asp Tyr  
 1 5 10 15  
 Val Arg Tyr Arg Leu Pro Leu Arg Val Val Lys His Phe Tyr Trp Thr  
 20 25 30  
 Ser Asp Ser Cys Pro Arg Pro Gly Val Val Leu Leu Thr Phe Arg Asp  
 35 40 45  
 Lys Glu Ile Cys Ala Asp Pro Arg Val Pro Tyr Leu Lys Met Ile Leu  
 50 55 60  
 Asn Lys Leu Ser Gln  
 65

## (2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 69 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:


Gly Pro Tyr Gly Ala Asn Met Glu Asp Ser Val Cys Cys Arg Asp Tyr  
 1 5 10 15  
 Val Arg Tyr Arg Leu Pro Leu Arg Val Val Lys Glu Tyr Phe Tyr Thr  
 20 25 30  
 Ser Asp Ser Cys Pro Arg Pro Gly Val Val Leu Leu Thr Phe Arg Asp  
 35 40 45  
 Lys Glu Ile Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu  
 50 55 60  
 Asn Lys Leu Ser Gln  
 65

-85-

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page _____, line _____	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution American Type Culture Collection (ATCC)	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville MD 20852 United States of America	
Date of deposit 04 June 1996	Accession Number HB-12122
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
Depositor: ICOS Corporation The deposit was made pursuant to the provisions of the Budapest Treaty Deposit: Hybridoma 191D	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">For receiving Office use only</div> <div style="padding: 5px;"><input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center; margin-top: 10px;"> Authorized officer</div></div>	<div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">For International Bureau use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on: <div style="text-align: center; margin-top: 10px;">Authorized officer</div></div>
---	---

- 86 -

**CLAIMS**

What is claimed is:

1. A purified polynucleotide encoding a polypeptide having the Macrophage Derived Chemokine (MDC) amino acid sequence of SEQ ID NO:  
5 2.
2. The polynucleotide of claim 1 which is a DNA.
3. The DNA of claim 2 having nucleotides 20 to 298 of SEQ  
ID NO: 1.
4. A purified polynucleotide encoding MDC amino acids 1 to  
10 69 of SEQ ID NO: 2.
5. The polynucleotide of claim 4 which is a DNA.
6. The DNA of claim 5 having nucleotides 92 to 298 of SEQ  
ID NO: 1.



- 87 -

7. A purified polynucleotide selected from the group consisting of:

- 5
- (a) the DNA of SEQ ID NO: 1;
- (b) a polynucleotide which hybridizes under stringent conditions to the non-coding strand of the DNA of SEQ ID NO: 1;
- 10
- (c) a polynucleotide which, but for the redundancy of the genetic code, would hybridize under stringent conditions to the non-coding strand of the DNA of SEQ ID NO: 1; and
- (d) a polynucleotide which encodes the same MDC polypeptide as the DNA of SEQ ID NO: 1.

8. The polynucleotide of claim 7 which is a DNA.

9. A purified polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 25.

15

10. The polynucleotide of claim 9 which is a DNA.

11. A purified polynucleotide encoding amino acids 1 to 69 of SEQ ID NO: 25.

12. The polynucleotide of claim 11 which is a DNA.

- 88 -

13. A purified polynucleotide selected from the group consisting of:

- 5
- (a) the DNA of claim 12;
  - (b) a polynucleotide which hybridizes under stringent conditions to the DNA of claim 12; and
  - (c) a polynucleotide which, but for the redundancy of the genetic code, would hybridize under stringent conditions to the DNA of claim 12.

14. The polynucleotide of claim 13 which is a DNA.

10 15. A vector comprising the DNA of claim 2, 5, 8, 10, 12, or 14.

16. The vector of claim 15 that is an expression vector, wherein the DNA is operatively linked to an expression control DNA sequence.

15 17. A host cell stably transformed or transfected with a DNA according to claim 2 or 5 in a manner allowing the expression in said host cell of MDC.

20 18. A method for producing MDC, said method comprising growing a host cell according to claim 17 in a nutrient medium and isolating the MDC from said cell or said medium.

19. A host cell stably transformed or transfected with a DNA according to claims 10 or 12 in a manner allowing the expression in said host cell of an MDC polypeptide analog.

- 89 -

20. A method for producing an MDC polypeptide analog, said method comprising growing a host cell according to claim 19 in a nutrient medium and isolating the MDC polypeptide analogue from said cell or said medium.

5                   21. A purified polypeptide having an amino acid sequence of SEQ ID NO: 25.

22. A purified polypeptide according to claim 21 having an amino acids sequence of SEQ ID NO: 2.

10                   23. A purified polypeptide having amino acids 1 to 69 of SEQ ID NO: 25.

24. A purified polypeptide according to claim 23 having amino acids 1 to 69 of SEQ ID NO: 2.

25. A polypeptide selected from the group consisting of:

15                   (a) a polypeptide comprising a sequence of amino acids identified by positions 1 to 70 of SEQ ID NO: 30;

(b) a purified polypeptide comprising a sequence of amino acids identified by positions 9 to 69 of SEQ ID NO: 2;

(c) a polypeptide comprising a sequence of amino acids identified by positions 1 to 69 of SEQ ID NO: 31; and

20                   (d) a polypeptide comprising a sequence of amino acids identified by positions 1 to 69 of SEQ ID NO: 32.

26. A polynucleotide encoding a polypeptide according to claim 25.

- 90 -

27. A polynucleotide according to claim 26 which is a DNA.
28. A vector comprising the DNA of claim 27.
29. A host cell stably transformed or transfected with a DNA according to claim 27, in a manner allowing expression in said host cell of  
5 said polypeptide.
30. An antibody specifically reactive with a polypeptide according to claim 21, 22, 23, 24, or 25.
31. An antibody according to claim 30 which is a monoclonal antibody.
- 10 32. A hybridoma cell line producing the antibody of claim 31.
33. Polyclonal antisera comprising an antibody according to claim 30.
34. An antibody specifically reactive with MDC.
- 15 35. A method for modulating leukocyte chemotaxis in a mammalian host comprising the step of:  
(a) administering to said mammalian host a polypeptide according to claim 21, 22, 23, 24, or 25, wherein said polypeptide modulates leukocyte chemotaxis in said host.
- 20 36. The method of claim 35 wherein said leukocytes are selected from the group consisting of monocytes and macrophages.

- 91 -

37. A method for palliating an inflammatory condition in a patient, said condition characterized by at least one of (i) monocyte chemotaxis toward a site of inflammation in said patient or (ii) fibroblast cell proliferation, said method comprising the step of:

- 5 (a) administering to said patient a therapeutically effective amount of MDC.

38. The method according to claim 37 wherein said therapeutically effective amount of MDC is an amount capable of inhibiting monocyte chemotaxis.

- 10 39. The method according to claim 37 wherein said therapeutically effective amount of MDC is an amount capable of inhibiting fibroblast cell proliferation.

40. A DNA comprising a continuous portion of the nucleotide sequence of SEQ ID NO: 1 or of the non-coding strand complementary thereto,

said continuous portion comprising at least 18 nucleotides,

said DNA being capable of hybridizing under stringent conditions to a human MDC gene.

41. A DNA according to claim 40 wherein said DNA fails to hybridize under said stringent conditions to a human chemokine gene selected from the group consisting of MCP-1 genes, MCP-2 genes, MCP-3 genes, RANTES genes, MIP-1 $\alpha$  genes, MIP-1 $\beta$  genes, and I-309 genes.

42. A pharmaceutical composition comprising a polypeptide according to claim 21, 22, 23, 24, or 25 in a pharmaceutically acceptable carrier.

- 92 -

43. The use of a composition according to claim 42 for the treatment of an inflammatory disease state.

44. The use according to claim 43 wherein said inflammatory disease state is characterized by monocyte chemotaxis toward a site of inflammation in a patient having said disease state.

5

45. The use according to claim 43 wherein said inflammatory disease state is characterized by fibroblast cell proliferation in a patient having said disease state.

- 93 -

46. A method for identifying a chemical compound having MDC modulating activity comprising the steps of:


- (a) providing first and second receptor compositions comprising MDC receptors;
- 5       (b) providing a control composition comprising detectably-labeled MDC.
- (c) providing a test composition comprising detectably-labeled MDC and further comprising said chemical compound;
- (d) contacting the first receptor composition with the control  
10       composition under conditions wherein MDC is capable of binding to MDC receptors;
- (e) contacting the second receptor composition with the test composition under conditions wherein MDC is capable of binding to MDC receptors;
- 15       (f) washing the first and second receptor compositions to remove detectably-labeled MDC that is unbound to MDC receptors;
- (g) measuring detectably-labeled MDC in said first and second receptor compositions; and
- 20       (h) identifying a chemical compound having MDC modulating activity, wherein MDC modulating activity is correlated with a difference in detectably-labeled MDC between said first and said second receptor compositions.

# ALIGNMENT OF MDC to C-C CHEMOKINES


	Leader	/	Mature	
Hu MDC	MARLQTALLV	VLVLLAVALQ	ATEA	GPYGAN MEDSVCCRDY VRYRLPLRVV 50
Hu MCP-3	M-KASAAALLC	LLLTAAAFSP	QGLA	QPVGIN -TSTTCCYRF INKKIPKQRL 48
Hu MCP-1	M-KVSAALLC	LLLIAATFIP	QGLA	QPDAIN -APVTCCYNF TNRKISVQRL 48
Hu MCP-2				QPD-SV SIPITCCFNV INRKIPQRL 26
Hu RANTES	M-KVSAALA	VILIAATALCA	PASA	SPY-SS -DTTPCCFAY IARPLPRAHI 47
Hu MIP-1β	M-KLCVTVLS	LLMLVAAFCS	PALS	APM-GS DPPTACCFSY T-REASSNFV 47
Hu MIP-1α	M-QVSTAALA	VLLCTMALCN	QF-S	ASL-AA DTPTACCFSY TSRQIPQNF 47
Hu I-309	MQIITTALVC	LLL-AGMWPE	DVDS	KS--MQ VPFSRCCFSF AEQEIPLRAI 47
Hu MDC	KH-FYWTSDS	CPRPGVLLT	FRDKEICADP	RVPWVKMILN KLSQ 93
Hu MCP-3	ESYRRITSSH	CPREAVIFKT	KLDKEICADP	TQKWVQDFMK HLDKKTQTPKL 99
Hu MCP-1	ASYRRITSSK	CPKEAVIFKT	IVAKEICADP	KQKWVQDSMD HLDKQTQTPKT 99
Hu MCP-2	ESYTRITNIQ	CPKEAVIFKT	KRGKEVCADP	KERWVRDSMK HLDQIFQNLKP 76
Hu RANTES	KEYFY-TSGK	CSNPVAVFVT	RKNRQVCANP	EKKWVREYIN SLEMS 91
Hu MIP-1β	VDY-YETSSL	CSQPAVVFQT	KRSKQVCADP	SESWVQEYVY DLELN 91
Hu MIP-1α	ADVF-ETSSQ	CSKPGVIFLT	KRSRQVCADP	SEEWQKYVS DLELSA 92
Hu I-309	LCY-RNTSSI	CSNEGLIFKL	KRGKEACALD	TVGWVQRHRK MLRHCPSKRK 96

Fig. 1




**Fig. 2**


3/8

**Fig. 3**


4/8

**Fig. 4**


5/8

**Fig. 5**

6/8

**Fig. 6**

7/8

**Fig. 7**

SUBSTITUTE SHEET (RULE 26)

8 / 8




Fig. 8

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/10114

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/19 C07K14/52 A61K38/19 C12N1/21 C12N5/10  
C07K16/24 C12N5/20 C12Q1/68 C12N15/11 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 310 136 (THE ROCKFELLER UNIVERSITY) 5 April 1989	
	---	
P,A	WO,A,95 17092 (HUMAN GENOME SCIENCE) 29 June 1995	
	-----	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

7 November 1996

Date of mailing of the international search report

19. 11. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Le Cornec, N



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/10114

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 35-39, 43-45  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although these claims are relates to a method of treatment of the human/animal body [(Rule 39.1(iv) PCT)] the search has been carried out and based on the alleged effects of the compound/ composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/10114

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-310136	05-04-89	AU-A- 2333688	27-07-89
		US-A- 5145676	08-09-92
-----			
WO-A-9517092	29-06-95	US-A- 5556767	17-09-96
		US-A- 5504003	02-04-96
		AU-A- 7549794	10-07-95
		CA-A- 2179606	29-06-95
		EP-A- 0735818	09-10-96
		ZA-A- 9403442	20-11-95
-----			

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**